<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) related complications in surgical patients - Gurusamy, KS - 2013 | Cochrane Library</title> <meta content="Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) related complications in surgical patients - Gurusamy, KS - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010268.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) related complications in surgical patients - Gurusamy, KS - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010268.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010268.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) related complications in surgical patients" name="citation_title"/> <meta content="Kurinchi Selvan Gurusamy" name="citation_author"/> <meta content="Royal Free Campus, UCL Medical School" name="citation_author_institution"/> <meta content="kurinchi2k@hotmail.com" name="citation_author_email"/> <meta content="Rahul Koti" name="citation_author"/> <meta content="Royal Free Campus, UCL Medical School" name="citation_author_institution"/> <meta content="Peter Wilson" name="citation_author"/> <meta content="University College London Hospitals" name="citation_author_institution"/> <meta content="Brian R Davidson" name="citation_author"/> <meta content="Royal Free Campus, UCL Medical School" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD010268.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/08/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010268.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010268.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010268.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Antibiotic Prophylaxis [adverse effects]; *Methicillin‐Resistant Staphylococcus aureus; Amoxicillin‐Potassium Clavulanate Combination [therapeutic use]; Anti‐Bacterial Agents [adverse effects, *therapeutic use]; Carrier State [microbiology]; Cefotaxime [therapeutic use]; Postoperative Complications [microbiology, prevention &amp; control]; Randomized Controlled Trials as Topic; Staphylococcal Infections [microbiology, *prevention &amp; control]; Surgical Wound Infection [microbiology, *prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010268.pub2&amp;doi=10.1002/14651858.CD010268.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="bzu3XIhG";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010268\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010268\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010268\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010268\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010268.pub2",title:"Antibiotic prophylaxis for the prevention of methicillin\\u2010resistant Staphylococcus aureus (MRSA) related complications in surgical patients",firstPublishedDate:"Aug 19, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Wounds Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010268.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010268.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010268.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010268.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010268.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010268.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010268.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010268.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010268.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010268.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4509 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010268.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/full#CD010268-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/full#CD010268-sec-0089"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/full#CD010268-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/full#CD010268-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/full#CD010268-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/full#CD010268-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/full#CD010268-sec-0059"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/full#CD010268-sec-0083"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/appendices#CD010268-sec-0094"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/table_n/CD010268StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/table_n/CD010268StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) related complications in surgical patients </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/information#CD010268-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Kurinchi Selvan Gurusamy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/information#CD010268-cr-0003">Rahul Koti</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/information#CD010268-cr-0004">Peter Wilson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010268.pub2/information#CD010268-cr-0005">Brian R Davidson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/information/en#CD010268-sec-0098">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 August 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010268.pub2">https://doi.org/10.1002/14651858.CD010268.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010268-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010268-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010268-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010268-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010268-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010268-abs-0001" lang="en"> <section id="CD010268-sec-0001"> <h3 class="title" id="CD010268-sec-0001">Background</h3> <p>Risk of methicillin‐resistant <i>Staphylococcus aureus</i> (MRSA) infection after surgery is generally low, but affects up to 33% of patients after certain types of surgery. Postoperative MRSA infection can occur as surgical site infections (SSIs), chest infections, or bloodstream infections (bacteraemia). The incidence of MRSA SSIs varies from 1% to 33% depending upon the type of surgery performed and the carrier status of the individuals concerned. The optimal prophylactic antibiotic regimen for the prevention of MRSA after surgery is not known. </p> </section> <section id="CD010268-sec-0002"> <h3 class="title" id="CD010268-sec-0002">Objectives</h3> <p>To compare the benefits and harms of all methods of antibiotic prophylaxis in the prevention of postoperative MRSA infection and related complications in people undergoing surgery. </p> </section> <section id="CD010268-sec-0003"> <h3 class="title" id="CD010268-sec-0003">Search methods</h3> <p>In March 2013 we searched the following databases: The Cochrane Wounds Group Specialised Register; The Cochrane Central Register of Controlled Trials (CENTRAL); Database of Abstracts of Reviews of Effects (DARE) (<i>The Cochrane Library</i> ); NHS Economic Evaluation Database (<i>The Cochrane Library</i> ); Health Technology Assessment (HTA) Database (<i>The Cochrane Library</i>); Ovid MEDLINE; Ovid MEDLINE (In‐Process &amp; Other Non‐Indexed Citations); Ovid EMBASE; and EBSCO CINAHL. </p> </section> <section id="CD010268-sec-0004"> <h3 class="title" id="CD010268-sec-0004">Selection criteria</h3> <p>We included only randomised controlled trials (RCTs) that compared one antibiotic regimen used as prophylaxis for SSIs (and other postoperative infections) with another antibiotic regimen or with no antibiotic, and that reported the methicillin resistance status of the cultured organisms. We did not limit our search for RCTs by language, publication status, publication year, or sample size. </p> </section> <section id="CD010268-sec-0005"> <h3 class="title" id="CD010268-sec-0005">Data collection and analysis</h3> <p>Two review authors independently identified the trials for inclusion in the review, and extracted data. We calculated the risk ratio (RR) with 95% confidence intervals (CI) for comparing binary outcomes between the groups and planned to calculated the mean difference (MD) with 95% CI for comparing continuous outcomes. We planned to perform meta‐analysis using both a fixed‐effect model and a random‐effects model. We performed intention‐to‐treat analysis whenever possible. </p> </section> <section id="CD010268-sec-0006"> <h3 class="title" id="CD010268-sec-0006">Main results</h3> <p>We included 12 RCTs, with 4704 participants, in this review. Eleven trials performed a total of 16 head‐to‐head comparisons of different prophylactic antibiotic regimens. Antibiotic prophylaxis was compared with no antibiotic prophylaxis in one trial. All the trials were at high risk of bias. With the exception of one trial in which all the participants were positive for nasal carriage of MRSA or had had previous MRSA infections, it does not appear that MRSA was tested or eradicated prior to surgery; nor does it appear that there was high prevalence of MRSA carrier status in the people undergoing surgery. </p> <p>There was no sufficient clinical similarity between the trials to perform a meta‐analysis. The overall all‐cause mortality in four trials that reported mortality was 14/1401 (1.0%) and there were no significant differences in mortality between the intervention and control groups in each of the individual comparisons. There were no antibiotic‐related serious adverse events in any of the 561 people randomised to the seven different antibiotic regimens in four trials (three trials that reported mortality and one other trial). None of the trials reported quality of life, total length of hospital stay or the use of healthcare resources. Overall, 221/4032 (5.5%) people developed SSIs due to all organisms, and 46/4704 (1.0%) people developed SSIs due to MRSA. </p> <p>In the 15 comparisons that compared one antibiotic regimen with another, there were no significant differences in the proportion of people who developed SSIs. In the single trial that compared an antibiotic regimen with placebo, the proportion of people who developed SSIs was significantly lower in the group that received antibiotic prophylaxis with co‐amoxiclav (or cefotaxime if allergic to penicillin) compared with placebo (all SSI: RR 0.26; 95% CI 0.11 to 0.65; MRSA SSI RR 0.05; 95% CI 0.00 to 0.83). In two trials that reported MRSA infections other than SSI<b>,</b> 19/478 (4.5%) people developed MRSA infections including SSI, chest infection and bacteraemia. There were no significant differences in the proportion of people who developed MRSA infections at any body site in these two comparisons. </p> </section> <section id="CD010268-sec-0007"> <h3 class="title" id="CD010268-sec-0007">Authors' conclusions</h3> <p>Prophylaxis with co‐amoxiclav decreases the proportion of people developing MRSA infections compared with placebo in people without malignant disease undergoing percutaneous endoscopic gastrostomy insertion, although this may be due to decreasing overall infection thereby preventing wounds from becoming secondarily infected with MRSA. There is currently no other evidence to suggest that using a combination of multiple prophylactic antibiotics or administering prophylactic antibiotics for an increased duration is of benefit to people undergoing surgery in terms of reducing MRSA infections. Well designed RCTs assessing the clinical effectiveness of different antibiotic regimens are necessary on this topic. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010268-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010268-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010268-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010268-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010268-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010268-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010268-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010268-abs-0004" lang="en"> <h3>Using an antibiotic to prevent MRSA (methicillin‐resistant Staphylococcus aureus) infections and related complications in people having surgery </h3> <p>Most bacterial wound infections after surgery heal naturally or after treatment with antibiotics.  Some bacteria are resistant to commonly‐used antibiotics, e.g. methicillin‐resistant <i>Staphylococcus aureus</i> (MRSA). MRSA infection after surgery is rare, but can occur in wounds (surgical site infections, or SSI), the chest, or bloodstream (bacteraemia), and can be life‐threatening. MRSA SSIs occur in 1% to 33% of people having surgery (depending on the type of operation) and result in extended hospitalisation. </p> <p>Antibiotics can be used individually, or combined, and administered for different durations. To identify the best antibiotic(s), or dose pattern, for preventing development of MRSA infection after surgery, we investigated studies that compared different antibiotics with each other, or with no treatment, to prevent MRSA SSIs. We included only randomised controlled trials (RCTs), and set no limits regarding language, or date, of publication, or trial size. Two review authors identified studies and extracted data independently. </p> <p>We identified 12 RCTs, with 4704 participants. Eleven trials compared 16 preventative (prophylactic) antibiotic treatments, and one compared antibiotic prophylaxis with no prophylaxis. Generally, MRSA status of the participants prior to surgery was not known. </p> <p>Four studies reported deaths (14/1401 participants): approximately 1% of participants died from any cause after surgery, but there were no significant differences between treatment groups. Four trials reported on serious antibiotic‐related adverse events ‐ there were none in 561 participants. None of the trials reported quality of life, length of hospital stay or use of healthcare resources. Overall, 221 SSIs due to any bacterium developed in 4032 people (6%), and 46 MRSA SSIs developed in 4704 people (1%). There were no significant differences in development of SSIs between the 15 comparisons of one antibiotic treatment against another. When antibiotic prophylaxis with co‐amoxiclav was compared with no antibiotic prophylaxis, a significantly lower proportion of people developed SSIs after receiving co‐amoxiclav (74% reduction in all SSIs, and 95% reduction in MRSA SSIs). </p> <p>Two trials reported that 19 participants developed MRSA infection in wounds (SSIs), chest, or bloodstream, but there were no significant differences in the proportion of people who developed them between the two comparisons. </p> <p>Prophylaxis with co‐amoxiclav decreases the proportion of people developing MRSA infections compared with no antibiotic prophylaxis in people without cancer undergoing surgery for feeding tube insertion into the stomach using endoscopy, although this may be due to decreasing overall infection thereby preventing wounds from becoming secondarily infected with MRSA. There is currently no other evidence that either a combination of prophylactic antibiotics, or increased duration of antibiotic treatment, benefits people undergoing surgery in terms of reducing MRSA infections. Well‐designed RCTs are necessary to assess different antibiotic treatments for preventing MRSA infections after surgery. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010268-sec-0089" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010268-sec-0089"></div> <h3 class="title" id="CD010268-sec-0090">Implications for practice</h3> <section id="CD010268-sec-0090"> <p>Prophylaxis with co‐amoxiclav decreases the proportion of people developing MRSA infections compared with placebo in people without malignant disease undergoing percutaneous endoscopic gastrostomy insertion, although this may be due to decreasing overall infection thereby preventing wounds from becoming secondarily infected with MRSA. There is currently no other evidence to suggest that using a combination of multiple prophylactic antibiotics or administering prophylactic antibiotics for an increased duration is of benefit in people undergoing surgery. However, the confidence intervals were wide. </p> </section> <h3 class="title" id="CD010268-sec-0091">Implications for research</h3> <section id="CD010268-sec-0091"> <p>Well designed randomised controlled trials are necessary on this topic. Such studies should use patient‐oriented outcomes such as mortality, serious adverse events, quality of life, total length of hospital stay (due to surgery or MRSA infection), use of health care resources (e.g. hospital visits due to MRSA infection), and MRSA infections at sites other than the surgical site. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010268-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010268-sec-0022"></div> <div class="table" id="CD010268-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) infections and related complications in surgical patients: mortality</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> surgical patients<br/> <b>Settings:</b> secondary<br/> <b>Intervention:</b> comparison of different regimens of prophylactic antibiotic regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comparisons</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Comparison of different regimens of prophylactic antibiotic regimens</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>One dose of cefotiam or cefmetazol versus four doses of cefotiam or cefmetazol (elective surgery for colon cancer)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kanamycin, erythromycin and cefotiam versus cefotiam (surgery for colorectal diseases)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Co‐amoxiclav or cefotaxime versus placebo (percutaneous endoscopic gastrostomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>146 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>79 per 1000</b> <br/> (25 to 251) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.54</b> <br/> (0.17 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vancomycin versus cefuroxime (coronary artery bypass graft without valvular disease)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> <br/> (0 to 50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.02</b> <br/> (0.18 to 22.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>884<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk in the study. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> The risk of bias in the trial was high<br/> <sup>2</sup> The confidence intervals overlapped 1 and/or 0.75 and 1.25. There were fewer than 300 events in total in the intervention and control groups </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010268-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) infections and related complications in surgical patients: surgical site infection</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b>Surgical site infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> surgical patients<br/> <b>Settings:</b> secondary<br/> <b>Intervention:</b> comparison of different regimens of prophylactic antibiotic regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comparisons</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Comparison of different regimens of prophylactic antibiotic regimens</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cefamendole versus cefamendole and gentamycin (median sternotomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 5.08</b> <br/> (0.24 to 105.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>522<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> <br/> (1 to 526) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cefazolin versus cefamendole (median sternotomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b> <br/> (6 to 131) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.55</b> <br/> (0.75 to 16.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>514<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cefazolin versus cefazolin and gentamycin (median sternotomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> <br/> (10 to 75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> <br/> (0.32 to 2.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>508<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Co‐amoxiclav or cefotaxime versus placebo (percutaneous endoscopic gastrostomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>98 per 1000</b> <br/> (41 to 244) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.26</b> <br/> (0.11 to 0.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daptomycin and cefazolin versus cefazolin (vascular surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b> <br/> (9 to 177) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.3</b> <br/> (0.07 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kanamycin, erythromycin and cefotiam versus cefotiam (surgery for colorectal diseases)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>110 per 1000</b> <br/> (50 to 242) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.46</b> <br/> (0.21 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Levofloxacin versus ofloxacin (breast cancer)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> <br/> (11 to 146) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.66</b> <br/> (0.18 to 2.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>One day of piperacillin, cefazolin, cefmetazole, or cefotiam versus three days of piperacillin, cefazolin, cefmetazole, or cefotiam (elective colorectal surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b> <br/> (28 to 116) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b> <br/> (0.52 to 2.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>One dose of cefotiam or cefmetazol versus four doses of cefotiam or cefmetazol (elective surgery for colon cancer)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>51 per 1000</b> <br/> (19 to 134) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.79</b> <br/> (0.3 to 2.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pefloxacin versus cefazolin and oxacillin (tibial fracture requiring external fixation)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>90 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> <br/> (39 to 115) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b> <br/> (0.43 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>616<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vancomycin and cefazolin versus cefazolin (open fractures)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> <br/> (23 to 327) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1</b> <br/> (0.27 to 3.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vancomycin and cefazolin versus cefazolin (vascular surgery) ‐ suggest add for all comparisons</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> <br/> (49 to 323) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b> <br/> (0.38 to 2.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vancomycin and cefazolin versus daptomycin and cefazolin (vascular surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> <br/> (27 to 575) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.19</b> <br/> (0.69 to 14.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vancomycin versus teicoplanin (paediatric cardiac surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No infection in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vancomycin versus cefuroxime (coronary artery bypass graft without valvular disease)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> <br/> (17 to 70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/> (0.53 to 2.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>884<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> is the control group risk in the study. When there were no events in either group, we have indicated so. When there were events in the intervention group but not in the control group, we have used a moderate proportion of 0.5% in the control group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> The risk of bias in the trial was high<br/> <sup>2</sup> The confidence intervals overlapped 1 and/or 0.75 and 1.25. There were fewer than 300 events in total in the intervention and control groups </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010268-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) infections and related complications in surgical patients: MRSA surgical site infection</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>MRSA surgical site infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> surgical patients<br/> <b>Settings:</b> secondary<br/> <b>Intervention:</b> comparison of different regimens of prophylactic antibiotic regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comparisons</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Comparison of different regimens of prophylactic antibiotic regimens</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cefamendole versus cefamendole and gentamycin (median sternotomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No infection in either group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>522<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cefazolin and gentamycin versus cefamendole and gentamycin (median sternotomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No infection in either group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>516<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cefazolin versus cefamendole (median sternotomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.05</b> <br/> (0.12 to 74.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>514<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> <br/> (1 to 372) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Cefazolin versus cefazolin and gentamycin (median sternotomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 2.98</b> <br/> (0.12 to 72.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>508<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>15 per 1000</b> <br/> (1 to 364) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐amoxiclav or cefotaxime versus placebo (percutaneous endoscopic gastrostomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>9 per 1000</b> <br/> (0 to 156) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.05</b> <br/> (0 to 0.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Daptomycin and cefazolin versus cefazolin (vascular surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>8 per 1000</b> <br/> (0 to 159) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.24</b> <br/> (0.01 to 4.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ertapenem versus cefotetan (elective colorectal surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>15 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>9 per 1000</b> <br/> (2 to 37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.59</b> <br/> (0.14 to 2.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>672<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Kanamycin, erythromycin and cefotiam versus cefotiam (surgery for colorectal diseases)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>55 per 1000</b> <br/> (10 to 294) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.97</b> <br/> (0.37 to 10.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Levofloxacin versus ofloxacin (breast cancer)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>No infection in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>181<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>One day of piperacillin, cefazolin, cefmetazole, or cefotiam versus three days of piperacillin, cefazolin, cefmetazole, or cefotiam (elective colorectal surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>No infection in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>521<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>One dose of cefotiam or cefmetazol versus four doses of cefotiam or cefmetazol (elective surgery for colon cancer)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>22 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>22 per 1000</b> <br/> (5 to 107) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.02</b> <br/> (0.21 to 4.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>275<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pefloxacin versus cefazolin and oxacillin (tibial fracture requiring external fixation)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>3 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>13 per 1000</b> <br/> (1 to 113) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.8</b> <br/> (0.43 to 33.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>616<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Vancomycin and cefazolin versus cefazolin (open fractures)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 3</b> <br/> (0.13 to 71.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>92<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>15 per 1000</b> <br/> (1 to 359) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vancomycin and cefazolin versus cefazolin (vascular surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>71 per 1000</b> <br/> (14 to 375) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.21</b> <br/> (0.42 to 11.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Vancomycin and cefazolin versus daptomycin and cefazolin (vascular surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 8.21</b> <br/> (0.45 to 148.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>107<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>41 per 1000</b> <br/> (2 to 744) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vancomycin versus teicoplanin (paediatric cardiac surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>No infection in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vancomycin versus cefuroxime (coronary artery bypass graft without valvular disease)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>5 per 1000</b> <br/> (1 to 32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.01</b> <br/> (0.14 to 7.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>884<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk in the study. When there were no events in either group, we have indicated so. When there were events in the intervention group but not in the control group, we have used a moderate proportion of 0.5% in the control group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> The risk of bias in the trial was high<br/> <sup>2</sup> The confidence intervals overlapped 1 and/or 0.75 and 1.25. There were fewer than 300 events in total in the intervention and control groups </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010268-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) infections and related complications in surgical patients: overall MRSA infections</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>Overall MRSA infections</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> surgical patients<br/> <b>Settings:</b> secondary<br/> <b>Intervention:</b> comparison of different regimens of prophylactic antibiotic regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comparisons</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Comparison of different regimens of prophylactic antibiotic regimens</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>One dose of cefotiam or cefmetazol versus four doses of cefotiam or cefmetazol (elective surgery for colon cancer)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> <br/> (5 to 97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.77</b> <br/> (0.17 to 3.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kanamycin, erythromycin and cefotiam versus cefotiam (surgery for colorectal diseases)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>111 per 1000</b> <br/> (35 to 353) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.97</b> <br/> (0.62 to 6.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk in the study. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> The risk of bias in the trial was high.<br/> <sup>2</sup> The confidence intervals overlapped 1 and/or 0.75 and 1.25. There were fewer than 300 events in total in the intervention and control groups. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010268-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010268-sec-0023"></div> <section id="CD010268-sec-0024"> <h3 class="title" id="CD010268-sec-0024">Description of the condition</h3> <p>Methicillin‐resistant <i>Staphylococcus aureus</i> (MRSA) was first discovered in 1961 (<a href="./references#CD010268-bbs2-0036" title="BarberM . Methicillin‐resistant staphylococci. Journal of Clinical Pathology1961;14:385‐93. ">Barber 1961</a>; <a href="./references#CD010268-bbs2-0061" title="JevonsPM . “Celbenin” ‐ resistant Staphylococci. British Medical Journal1961;1(5219):124‐5. ">Jevons 1961</a>; <a href="./references#CD010268-bbs2-0067" title="KnoxR , SmithJT . The nature of penicillin resistance in staphylococci. Lancet1961;2(7201):520‐2. ">Knox 1961</a>), and outbreaks of infection have been reported since the 1970s (<a href="./references#CD010268-bbs2-0066" title="KlimekJJ , MarsikFJ , BartlettRC , WeirB , SheaP , QuintilianiR . Clinical, epidemiologic and bacteriologic observations of an outbreak of methicillin‐resistant Staphylococcus aureus at a large community hospital. American Journal of Medicine1976;61(3):340‐5. ">Klimek 1976</a>; <a href="./references#CD010268-bbs2-0078" title="O'TooleRD , DrewWL , DahlgrenBJ , BeatyHN . An outbreak of methicillin‐resistant Staphylococcus aureus infection. Observations in hospital and nursing home. JAMA1970;213(2):257‐63. ">O'Toole 1970</a>). MRSA infection is associated with significant mortality and morbidity. In the European Union member states plus Norway and Iceland, MRSA infections cause an estimated one million extra hospital stays and cost an estimated EUR 600 million (<a href="./references#CD010268-bbs2-0046" title="ECDC . European Centre for Disease Prevention and Control. Annual epidemiological report on communicable diseases in Europe. http://www.ecdc.europa.eu/en/publications/Publications/0910_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf 2009 (accessed on 17 July 2011). ">ECDC 2009a</a>). In the USA, an estimated 125,000 hospitalisations occur each year in relation to MRSA infections (<a href="./references#CD010268-bbs2-0068" title="KuehnertMJ , HillHA , KupronisBA , TokarsJI , SolomonSL , JerniganDB . Methicillin‐resistant–Staphylococcus aureus hospitalizations, United States. Emerging Infectious Diseases2005;11(6):868‐72. ">Kuehnert 2005</a>). While there has been a decrease in the incidence of MRSA in some countries such as the USA (<a href="./references#CD010268-bbs2-0062" title="KallenAJ , MuY , BulensS , ReingoldA , PetitS , GershmanK , et al. Health care‐associated invasive MRSA infections, 2005‐2008. JAMA2010;304(6):641‐8. ">Kallen 2010</a>), probably because of measures to combat MRSA infections (<a href="./references#CD010268-bbs2-0047" title="ECDC . European Centre for Disease Prevention and Control. The bacterial challenge: time to react. A call to narrow the gap between multi‐drug resistant bacteria in the EU and the development of new anti‐bacterial agents. http://www.ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf 2009 (accessed on 17 July 2011). ">ECDC 2009b</a>), there has been an increase in the incidence of MRSA infections in Nordic countries (<a href="./references#CD010268-bbs2-0095" title="SkovR , SSAC MRSA Working Party. MRSA infections increasing in the Nordic countries. Euro Surveillance2005;10(31):E050804.2. ">Skov 2005</a>). Methicillin (meticillin is the International Nonproprietary Name but we have used 'methicillin' in this review as it is the more commonly used name in our experience) resistance is a marker of resistance to some beta‐lactam antibiotics (penicillin and the cephalosporin group of antibiotics, which are some of the most commonly used antibiotics in the patients) (<a href="./references#CD010268-bbs2-0080" title="OtterJA , FrenchGL . Community‐associated meticillin‐resistant Staphylococcus aureus strains as a cause of healthcare‐associated infection. Journal of Hospital Infection2011;79(3):189‐93. ">Otter 2011</a>). In addition to beta‐lactam antibiotics, MRSA may be resistant to many other commonly‐used antibiotics such as erythromycin, clindamycin, gentamycin, ciprofloxacin, and fusidic acid (<a href="./references#CD010268-bbs2-0080" title="OtterJA , FrenchGL . Community‐associated meticillin‐resistant Staphylococcus aureus strains as a cause of healthcare‐associated infection. Journal of Hospital Infection2011;79(3):189‐93. ">Otter 2011</a>). So, even though the antibiotic methicillin is not commonly used itself, methicillin resistance indicates resistance to a wide range of antibiotics. There are currently concerns that farm animals may become reservoirs of MRSA, and a source of a major epidemic of MRSA outside hospitals (<a href="./references#CD010268-bbs2-0099" title="WulfM , VossA . MRSA in livestock animals‐an epidemic waiting to happen?. Clinical Microbiology and Infection2008;14(6):519‐21. ">Wulf 2008</a>). </p> <p>The incidence of MRSA infection after surgery is usually low, but can be up to 33% in certain types of surgery, such as pancreatic surgery (pancreatoduodenectomies) (<a href="./references#CD010268-bbs2-0086" title="SanjayP , FawziA , KulliC , PolignanoFM , TaitIS . Impact of methicillin‐resistant Staphylococcus aureus (MRSA) infection on patient outcome after pancreatoduodenectomy (PD)‐‐a cause for concern?. Pancreas2010;39(8):1211‐4. ">Sanjay 2010</a>). Post‐operative MRSA infection can present as surgical site infections (SSI), chest infections, or bloodstream infections (bacteraemia) (<a href="./references#CD010268-bbs2-0049" title="FraserS , BradyR , GrahamC , Paterson‐BrownS , GibbA . Methicillin‐resistant staphylococcus aureus in surgical patients: Identification of high‐risk populations for the development of targeted screening programmes. Annals of the Royal College of Surgeons of England2010;92(4):311‐5. ">Fraser 2010</a>; <a href="./references#CD010268-bbs2-0083" title="ReddySL , GraysonAD , SmithG , WarwickR , ChalmersJA . Methicillin resistant Staphylococcus aureus infections following cardiac surgery: incidence, impact and identifying adverse outcome traits. European Journal of Cardio‐Thoracic Surgery2007;32(1):113‐7. ">Reddy 2007</a>; <a href="./references#CD010268-bbs2-0086" title="SanjayP , FawziA , KulliC , PolignanoFM , TaitIS . Impact of methicillin‐resistant Staphylococcus aureus (MRSA) infection on patient outcome after pancreatoduodenectomy (PD)‐‐a cause for concern?. Pancreas2010;39(8):1211‐4. ">Sanjay 2010</a>). Nosocomial (hospital‐acquired) MRSA transmission is believed to be due to cross‐contamination from healthcare workers whose hands become colonised transiently while performing patient care activities on people colonised or infected with MRSA (<a href="./references#CD010268-bbs2-0037" title="BoyceJM , JacksonMM , PuglieseG , BattMD , FlemingD , GarnerJS , et al. Methicillin‐resistant Staphylococcus aureus (MRSA): a briefing for acute care hospitals and nursing facilities. Infection Control and Hospital Epidemiology1994;15(2):105‐15. ">Boyce 1994</a>). Healthcare workers who are persistent nasal carriers of MRSA (i.e. who carry MRSA without suffering from infection) may also act as the source of infection for MRSA (<a href="./references#CD010268-bbs2-0037" title="BoyceJM , JacksonMM , PuglieseG , BattMD , FlemingD , GarnerJS , et al. Methicillin‐resistant Staphylococcus aureus (MRSA): a briefing for acute care hospitals and nursing facilities. Infection Control and Hospital Epidemiology1994;15(2):105‐15. ">Boyce 1994</a>). Generally, air‐borne transmission is not considered to be a mode of transmission for MRSA. Large burn wounds in people colonised or infected with MRSA may act as reservoirs of MRSA (<a href="./references#CD010268-bbs2-0037" title="BoyceJM , JacksonMM , PuglieseG , BattMD , FlemingD , GarnerJS , et al. Methicillin‐resistant Staphylococcus aureus (MRSA): a briefing for acute care hospitals and nursing facilities. Infection Control and Hospital Epidemiology1994;15(2):105‐15. ">Boyce 1994</a>). </p> <p>The Centers for Disease Control and Prevention (CDC) criteria for SSIs, published by Horan et al (<a href="./references#CD010268-bbs2-0059" title="HoranTC , GaynesRP , MartoneWJ , JarvisWR , EmoriTG . CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infection Control and Hospital Epidemiology1992;13(10):606‐8. ">Horan 1992</a>), provide definitions of nosocomial SSIs. Interested readers may refer to this document for definitions, but broadly speaking, infections confined to skin and subcutaneous tissues are superficial SSIs; those involving the fascia and muscles are deep SSIs; and those involving organs or spaces other than the incision are organ space SSIs (<a href="./references#CD010268-bbs2-0059" title="HoranTC , GaynesRP , MartoneWJ , JarvisWR , EmoriTG . CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infection Control and Hospital Epidemiology1992;13(10):606‐8. ">Horan 1992</a>). The incidence of MRSA SSIs in developed countries varies from 1% to 25% depending upon type of surgery and the carrier status of the individual (i.e. whether MRSA colonisation was present prior to the surgery) (<a href="./references#CD010268-bbs2-0053" title="HarbarthS , HuttnerB , GervazP , FankhauserC , ChraitiMN , SchrenzelJ , et al. Risk factors for methicillin‐resistant Staphylococcus aureus surgical site infection. Infection Control and Hospital Epidemiology2008;29(9):890‐3. ">Harbarth 2008a</a>; <a href="./references#CD010268-bbs2-0083" title="ReddySL , GraysonAD , SmithG , WarwickR , ChalmersJA . Methicillin resistant Staphylococcus aureus infections following cardiac surgery: incidence, impact and identifying adverse outcome traits. European Journal of Cardio‐Thoracic Surgery2007;32(1):113‐7. ">Reddy 2007</a>; <a href="./references#CD010268-bbs2-0085" title="RidgewayS , WilsonJ , CharletA , KafatosG , PearsonA , CoelloR . Infection of the surgical site after arthroplasty of the hip. Journal of Bone and Joint Surgery. British Volume2005;87(6):844‐50. ">Ridgeway 2005</a>; <a href="./references#CD010268-bbs2-0086" title="SanjayP , FawziA , KulliC , PolignanoFM , TaitIS . Impact of methicillin‐resistant Staphylococcus aureus (MRSA) infection on patient outcome after pancreatoduodenectomy (PD)‐‐a cause for concern?. Pancreas2010;39(8):1211‐4. ">Sanjay 2010</a>; <a href="./references#CD010268-bbs2-0091" title="ShuklaS , NixonM , AcharyaM , KorimMT , PandeyR . Incidence of MRSA surgical‐site infection in MRSA carriers in an orthopaedic trauma unit. Journal of Bone and Joint Surgery. British Volume2009;91(2):225‐8. ">Shukla 2009</a>). The role of universal MRSA screening and contact precautions in hospitalised patients is controversial. Guidelines published by the Society for Healthcare Epidemiology of America (SHEA) recommend routine screening and contact precautions (<a href="./references#CD010268-bbs2-0076" title="MutoCA , JerniganJA , OstrowskyBE , RichetHM , JarvisWR , BoyceJM , et al. SHEA guideline for preventing nosocomial transmission of multidrug‐resistant strains of Staphylococcus aureus and enterococcus. Infection Control and Hospital Epidemiology2003;24(5):362‐86. ">Muto 2003</a>); others suggest that MRSA screening targeted at people at high risk of MRSA colonisation, such as those requiring intensive care, people with chronic wounds, and nursing home residents is more cost‐effective than universal MRSA screening (<a href="./references#CD010268-bbs2-0043" title="CreamerE , GalvinS , DolanA , SherlockO , DimitrovBD , Fitzgerald‐HughesD , et al. Evaluation of screening risk and non risk patients for methicillin‐resistant Staphylococcus aureus on admission in an acute care hospital. American Journal of Infection Control2012;40(5):411‐5. ">Creamer 2011</a>; <a href="./references#CD010268-bbs2-0063" title="KangJ , MandsagerP , BiddleAK , WeberDJ . Cost‐effectiveness analysis of active surveillance screening for methicillin‐resistant Staphylococcus aureus in an academic hospital setting. Infection Control and Hospital Epidemiology2012;33(5):477‐86. ">Kang 2012</a>). Others suggest that the contact precautions are not necessary for decreasing post‐operative MRSA infection rate, provided that the people are isolated after screening (<a href="./references#CD010268-bbs2-0096" title="SpenceMR , DammelT , CourserS . Contact precautions for methicillin‐resistant Staphylococcus aureus colonization: costly and unnecessary?. American Journal of Infection Control2012;40(6):535‐8. ">Spence 2011</a>); yet others suggest that MRSA screening is not effective in decreasing post‐operative MRSA SSIs (<a href="./references#CD010268-bbs2-0054" title="HarbarthS , FankhauserC , SchrenzelJ , ChristensonJ , GervazP , Bandiera‐ClercC , et al. Universal screening for methicillin‐resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA2008;299(10):1149‐57. ">Harbarth 2008b</a>). The risk factors, other than the type of surgery and carrier status of the individual, include emergency surgery, prolonged duration of surgery, contaminated surgery, immunosuppression, and the presence of co‐morbidities such as diabetes mellitus, renal insufficiency, and ischaemic disease (<a href="./references#CD010268-bbs2-0053" title="HarbarthS , HuttnerB , GervazP , FankhauserC , ChraitiMN , SchrenzelJ , et al. Risk factors for methicillin‐resistant Staphylococcus aureus surgical site infection. Infection Control and Hospital Epidemiology2008;29(9):890‐3. ">Harbarth 2008a</a>). MRSA SSIs are associated with increased mortality in people undergoing cardiac operations such as coronary artery bypass graft surgery and cardiac valve surgery (<a href="./references#CD010268-bbs2-0083" title="ReddySL , GraysonAD , SmithG , WarwickR , ChalmersJA . Methicillin resistant Staphylococcus aureus infections following cardiac surgery: incidence, impact and identifying adverse outcome traits. European Journal of Cardio‐Thoracic Surgery2007;32(1):113‐7. ">Reddy 2007</a>). Cardiac surgical patients with MRSA SSIs had an in‐hospital mortality of 12.9% compared with an in‐hospital mortality of 3% in uninfected cardiac surgery patients (<a href="./references#CD010268-bbs2-0083" title="ReddySL , GraysonAD , SmithG , WarwickR , ChalmersJA . Methicillin resistant Staphylococcus aureus infections following cardiac surgery: incidence, impact and identifying adverse outcome traits. European Journal of Cardio‐Thoracic Surgery2007;32(1):113‐7. ">Reddy 2007</a>). In people undergoing vascular surgery, such as aortic aneurysm repair, carotid endarterectomy, and vascular bypass procedures, the presence of post‐operative MRSA infection resulted in a four‐fold increase in the in‐hospital mortality (<a href="./references#CD010268-bbs2-0042" title="CowieSE , MaI , LeeSK , SmithRM , HsiangYN . Nosocomial MRSA infection in vascular surgery patients: impact on patient outcome. Vascular and Endovascular Surgery2005;39(4):327‐34. ">Cowie 2005</a>). Patients who developed MRSA infections also stayed longer in hospital than those who did not develop MRSA infections (<a href="./references#CD010268-bbs2-0040" title="ChemalyRF , HachemRY , HusniRN , BahnaB , RjailiGA , WakedA , et al. Characteristics and outcomes of methicillin‐resistant Staphylococcus aureus surgical‐site infections in patients with cancer: a case‐control study. Annals of Surgical Oncology2010;17(6):1499‐506. ">Chemaly 2010</a>; <a href="./references#CD010268-bbs2-0042" title="CowieSE , MaI , LeeSK , SmithRM , HsiangYN . Nosocomial MRSA infection in vascular surgery patients: impact on patient outcome. Vascular and Endovascular Surgery2005;39(4):327‐34. ">Cowie 2005</a>; <a href="./references#CD010268-bbs2-0049" title="FraserS , BradyR , GrahamC , Paterson‐BrownS , GibbA . Methicillin‐resistant staphylococcus aureus in surgical patients: Identification of high‐risk populations for the development of targeted screening programmes. Annals of the Royal College of Surgeons of England2010;92(4):311‐5. ">Fraser 2010</a>; <a href="./references#CD010268-bbs2-0086" title="SanjayP , FawziA , KulliC , PolignanoFM , TaitIS . Impact of methicillin‐resistant Staphylococcus aureus (MRSA) infection on patient outcome after pancreatoduodenectomy (PD)‐‐a cause for concern?. Pancreas2010;39(8):1211‐4. ">Sanjay 2010</a>; <a href="./references#CD010268-bbs2-0091" title="ShuklaS , NixonM , AcharyaM , KorimMT , PandeyR . Incidence of MRSA surgical‐site infection in MRSA carriers in an orthopaedic trauma unit. Journal of Bone and Joint Surgery. British Volume2009;91(2):225‐8. ">Shukla 2009</a>). </p> <p>The incidence of post‐operative MRSA infection can vary with the type of surgery; such infection is usually rare, but post‐operative chest infections can be found in up to 15% of pancreatic surgeries (<a href="./references#CD010268-bbs2-0086" title="SanjayP , FawziA , KulliC , PolignanoFM , TaitIS . Impact of methicillin‐resistant Staphylococcus aureus (MRSA) infection on patient outcome after pancreatoduodenectomy (PD)‐‐a cause for concern?. Pancreas2010;39(8):1211‐4. ">Sanjay 2010</a>), and can result in bacteraemia in up to 5% of the pancreatic surgical patients (<a href="./references#CD010268-bbs2-0086" title="SanjayP , FawziA , KulliC , PolignanoFM , TaitIS . Impact of methicillin‐resistant Staphylococcus aureus (MRSA) infection on patient outcome after pancreatoduodenectomy (PD)‐‐a cause for concern?. Pancreas2010;39(8):1211‐4. ">Sanjay 2010</a>). MRSA bacteraemia is associated with a 30‐day mortality of about 28% to 38% (<a href="./references#CD010268-bbs2-0069" title="LamagniTL , PotzN , PowellD , PebodyR , WilsonJ , DuckworthG . Mortality in patients with meticillin‐resistant Staphylococcus aureus bacteraemia, England 2004‐2005. Journal of Hospital Infection2011;77(1):16‐20. ">Lamagni 2011</a>; <a href="./references#CD010268-bbs2-0071" title="LewisT , ChaudhryR , NightingaleP , LambertP , DasI . Methicillin‐resistant Staphylococcus aureus bacteremia: epidemiology, outcome, and laboratory characteristics in a tertiary referral center in the UK. International Journal of Infectious Diseases2011;15(2):e131‐5. ">Lewis 2011</a>; <a href="./references#CD010268-bbs2-0097" title="WangJT , WangJL , FangCT , ChieWC , LaiMS , LauderdaleTL , et al. Risk factors for mortality of nosocomial methicillin‐resistant Staphylococcus aureus (MRSA) bloodstream infection: with investigation of the potential role of community‐associated MRSA strains. Journal of Infection2010;61(6):449‐57. ">Wang 2010</a>), and a one‐year mortality of about 55% (<a href="./references#CD010268-bbs2-0064" title="KayeKS , AndersonDJ , ChoiY , LinkK , ThackerP , SextonDJ . The deadly toll of invasive methicillin‐resistant Staphylococcus aureus infection in community hospitals. Clinical Infectious Diseases2008;46(10):1568‐77. ">Kaye 2008</a>). </p> </section> <section id="CD010268-sec-0025"> <h3 class="title" id="CD010268-sec-0025">Description of the intervention</h3> <p>The Oxford English Dictionary defines an antibiotic substance as, "One of a class of substances produced by living organisms and capable of destroying or inhibiting the growth of micro‐organisms especially used for therapeutic purposes. Synthetic organic compounds having similar properties are also called antibiotics" (<a href="./references#CD010268-bbs2-0079" title="OED . Oxford English dictionary. The definitive record of the English language. http://www.oed.com/ 2011 (accessed on 7 April, 2011). ">OED 2011</a>). Prophylactic antibiotics (to prevent infection) require administration before the infection sets in. A variety of antibiotics, including beta‐lactams (penicillin derivatives, cephalosporins),glycopeptide antibiotics (e.g. vancomycin, teicoplanin), clindamycin, trimethoprim‐sulfamethoxazole (TMP‐SMX), a tetracycline (doxycycline or minocycline), linezolid, daptomycin, telavancin, rifampicin, gentamycin, and fluoroquinolone, all work against MRSA (<a href="./references#CD010268-bbs2-0072" title="LiuC , BayerA , CosgroveSE , DaumRS , FridkinSK , GorwitzRJ , et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin‐resistant Staphylococcus aureus infections in adults and children: executive summary. Clinical Infectious Diseases2011;52(3):285‐92. ">Liu 2011</a>). Different antibiotics are administered in different ways, with the common routes being oral, intravenous, and topical (surface) administration (<a href="./references#CD010268-bbs2-0072" title="LiuC , BayerA , CosgroveSE , DaumRS , FridkinSK , GorwitzRJ , et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin‐resistant Staphylococcus aureus infections in adults and children: executive summary. Clinical Infectious Diseases2011;52(3):285‐92. ">Liu 2011</a>). Antibiotics can be given as a single agent or in combinations (<a href="./references#CD010268-bbs2-0072" title="LiuC , BayerA , CosgroveSE , DaumRS , FridkinSK , GorwitzRJ , et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin‐resistant Staphylococcus aureus infections in adults and children: executive summary. Clinical Infectious Diseases2011;52(3):285‐92. ">Liu 2011</a>). Antibiotics can be given pre‐operatively, during the operation, post‐operatively, or a combination of the above. Prophylactic antibiotics are usually started just before surgery, and can vary between a single dose or multiple doses for a short period of time after the surgery (<a href="./references#CD010268-bbs2-0029" title="SaginurR , CroteauD , BergeronMG . Comparative efficacy of teicoplanin and cefazolin for cardiac operation prophylaxis in 3027 patients The ESPRIT Group. Journal of Thoracic and Cardiovascular Surgery2000;120(6):1120‐30. ">Saginur 2000</a>). An antibiotic regimen can be considered as a particular method of administration of antibiotic that includes route of administration, dose administered, and whether single or multiple antibiotics; it can be administered pre‐operatively, during the operation, post‐operatively, or a combination of the above. Some national guidelines recommend a single prophylactic dose prior to start of surgery except under exceptional circumstances, such as prolonged surgery (more than four hours), major blood loss (in excess of 1.5 litres in adults or 25 ml/kg in children), or in specific types of surgery such as arthroplasty (<a href="./references#CD010268-bbs2-0093" title="Scottish Intercollegiate Guidelines Network (SIGN). Antibiotic prophylaxis in surgery. A national clinical guideline. http://www.sign.ac.uk/pdf/sign104.pdf 2008 (accessed 14 February 2013); Vol. 104. ">SIGN 2008</a>). </p> </section> <section id="CD010268-sec-0026"> <h3 class="title" id="CD010268-sec-0026">How the intervention might work</h3> <p>The mechanisms of action vary for different types of antibiotic, but in general terms they either destroy MRSA or prevent cell division (which prevents reproduction and hence multiplication in numbers of MRSA bacteria). The intervention might decrease the complications caused by MRSA infection by preventing MRSA infection. As described above, complications related to MRSA infection include mortality and serious adverse events such as bacteraemia, and chest infection; such outcomes are important in terms of clinical decision making (<a href="./references#CD010268-bbs2-0049" title="FraserS , BradyR , GrahamC , Paterson‐BrownS , GibbA . Methicillin‐resistant staphylococcus aureus in surgical patients: Identification of high‐risk populations for the development of targeted screening programmes. Annals of the Royal College of Surgeons of England2010;92(4):311‐5. ">Fraser 2010</a>; <a href="./references#CD010268-bbs2-0083" title="ReddySL , GraysonAD , SmithG , WarwickR , ChalmersJA . Methicillin resistant Staphylococcus aureus infections following cardiac surgery: incidence, impact and identifying adverse outcome traits. European Journal of Cardio‐Thoracic Surgery2007;32(1):113‐7. ">Reddy 2007</a>; <a href="./references#CD010268-bbs2-0086" title="SanjayP , FawziA , KulliC , PolignanoFM , TaitIS . Impact of methicillin‐resistant Staphylococcus aureus (MRSA) infection on patient outcome after pancreatoduodenectomy (PD)‐‐a cause for concern?. Pancreas2010;39(8):1211‐4. ">Sanjay 2010</a>). Incidence of MRSA infection is considered to be an intermediate outcome that might influence mortality, and has serious adverse events. </p> </section> <section id="CD010268-sec-0027"> <h3 class="title" id="CD010268-sec-0027">Why it is important to do this review</h3> <p>One systematic review found that glycopeptide antibiotics (such as vancomycin and teicoplanin) did not influence post‐operative surgical site infection rates compared with non‐glycopeptide antibiotics (<a href="./references#CD010268-bbs2-0039" title="ChambersD , WorthyG , MyersL , WeatherlyH , ElliottR , HawkinsN , et al. Glycopeptide vs. non‐glycopeptide antibiotics for prophylaxis of surgical site infections: a systematic review. Surgical Infections2010;11(5):455‐62. ">Chambers 2010</a>). This is just of one of the comparisons included in this review. There has been no systematic review comparing other antibiotics. Loeb et al compared the use of different anti‐microbial treatments in people colonised with MRSA either nasally or at extra‐nasal sites and concluded that there was insufficient evidence to support use of topical or systemic (whole body) antimicrobial therapy for eradicating nasal or extra‐nasal MRSA (<a href="./references#CD010268-bbs2-0073" title="LoebMB , MainC , EadyA , Walkers‐DilksC . Antimicrobial drugs for treating methicillin‐resistant Staphylococcus aureus colonization. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD003340] ">Loeb 2003</a>).There has been no systematic review or Cochrane review comparing the various antibiotics, other than the comparison between vancomycin and teicoplanin by <a href="./references#CD010268-bbs2-0039" title="ChambersD , WorthyG , MyersL , WeatherlyH , ElliottR , HawkinsN , et al. Glycopeptide vs. non‐glycopeptide antibiotics for prophylaxis of surgical site infections: a systematic review. Surgical Infections2010;11(5):455‐62. ">Chambers 2010</a>, in the prevention of MRSA infection and subsequent complications in people undergoing surgery. Such a review will be a useful guide for microbiologists, surgeons, and policy makers. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010268-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010268-sec-0028"></div> <p>To compare the benefits and harms of all methods of antibiotic prophylaxis in the prevention of MRSA infection and related post‐operative complications in people undergoing surgery. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010268-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010268-sec-0029"></div> <section id="CD010268-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010268-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs), irrespective of blinding, language, publication status, date of publication, study setting, sample size, or whether the incidence of MRSA infection was the primary outcome of the trial. We planned to include cluster randomised clinical trials if the effect estimate was available after adjusting for clustering effect. No other study designs (i.e. quasi‐randomised studies and non‐randomised studies) were included. </p> </section> <section id="CD010268-sec-0032"> <h4 class="title">Types of participants</h4> <p>People undergoing surgery, irrespective of age, type of surgery, whether surgery was elective or emergency, and whether MRSA colonisation was identified by routine screening (in general, we expected that if MRSA colonisation was identified, it would have been eradicated before surgery). We excluded studies recruiting people with established MRSA SSIs, as these are covered in another review (<a href="./references#CD010268-bbs2-0051" title="GurusamyK , KotiR , ToonC , WilsonP , DavidsonBR . Antibiotic therapy for the treatment of methicillin‐resistant Staphylococcus aureus (MRSA) infections in surgical wounds. Cochrane Database of Systematic Reviews In Press. ">Gurusamy</a>). </p> </section> <section id="CD010268-sec-0033"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD010268-list-0001"> <li> <p>Comparison of antibiotic prophylaxis (irrespective of the antibiotic) compared with placebo (or no treatment). </p> </li> <li> <p>Comparison of different antibiotic prophylaxis (and regimens). This includes different doses, routes, or timings of administration. </p> </li> </ol> </p> <p>We included studies evaluating a combination of antibiotics in terms of the combined regimen rather than as single antibiotics. </p> </section> <section id="CD010268-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD010268-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010268-list-0002"> <li> <p>All‐cause mortality at maximal follow‐up.</p> </li> <li> <p>Other serious adverse events (defined as any event that is life‐threatening; requires inpatient hospitalisation; results in a persistent or significant disability; or any important medical event that might have jeopardised the patient or requires intervention to prevent it (<a href="./references#CD010268-bbs2-0060" title="International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Code of Federal Regulation &amp; ICH Guidelines. Media: Parexel Barnett, 1996. ">ICH‐GCP 1996</a>), e.g. rates of bacteraemia, and other MRSA complications) at maximal follow‐up due to surgery or MRSA infection or due to the use of antibiotics. Mild adverse events are unlikely to determine the clinical management, if there were no significant differences in the primary outcomes or one of the secondary outcomes. </p> </li> <li> <p>Quality of life (at maximal follow‐up).</p> </li> </ol> </p> </section> <section id="CD010268-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010268-list-0003"> <li> <p>Total length of hospital stay (at maximal follow‐up due to surgery or MRSA infection).</p> </li> <li> <p>Use of health care resources (e.g. hospital visits at maximal follow‐up due to surgery or MRSA infection). </p> </li> <li> <p>Rates of SSIs (due to all organisms) within 30 days of surgery.</p> </li> <li> <p>Rates of SSIs due to MRSA within 30 days of surgery.</p> </li> <li> <p>Rates of infections due to MRSA at any site within 30 days of surgery.</p> </li> </ol> </p> <p>We included only trials in which MRSA SSIs were reported.</p> </section> </section> </section> <section id="CD010268-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010268-sec-0038"> <h4 class="title">Electronic searches</h4> <p>In March 2013 we searched the following electronic databases to identify reports of relevant RCTs:  </p> <p> <ul id="CD010268-list-0004"> <li> <p>The Cochrane Wounds Group Specialised Register (searched 28 February 2013);</p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (<i>The Cochrane Library</i> CENTRAL) (2013, Issue 1); </p> </li> <li> <p>Database of Abstracts of Reviews of Effects (DARE) ) (<i>The Cochrane Library</i> 2013, Issue 1); </p> </li> <li> <p>NHS Economic Evaluation Database ) (<i>The Cochrane Library</i> 2013, Issue 1); </p> </li> <li> <p>Health Technology Assessment (HTA) Database ) (<i>The Cochrane Library</i> 2013, Issue 1); </p> </li> <li> <p>Ovid MEDLINE (1948 to February Week 3 2013);</p> </li> <li> <p>Ovid MEDLINE (In‐Process &amp; Other Non‐Indexed Citations, 28 February 2013);</p> </li> <li> <p>Ovid EMBASE (1974 to 2013 Week 08);</p> </li> <li> <p>EBSCO CINAHL (1982 to 21 February 2013).</p> </li> </ul> </p> <p>We used the following search strategy in The Cochrane Central Register of Controlled Trials (CENTRAL):<br/> <br/> #1 MeSH descriptor Methicillin Resistance explode all trees<br/> #2 MeSH descriptor Staphylococcal Infections explode all trees<br/> #3 MeSH descriptor Staphylococcus aureus explode all trees<br/> #4 (#2 OR #3)<br/> #5 (#1 AND #4)<br/> #6 MeSH descriptor Methicillin‐Resistant Staphylococcus aureus explode all trees<br/> #7 (methicillin NEXT resistan*) or (meticillin NEXT resistan*) or MRSA<br/> #8 (#5 OR #6 OR #7)<br/> #9 MeSH descriptor Wound Infection explode all trees<br/> #10 MeSH descriptor Sepsis explode all trees<br/> #11 MeSH descriptor Soft Tissue Infections explode all trees<br/> #12 MeSH descriptor Surgical Wound Dehiscence explode all trees<br/> #13 surg* NEAR/5 infect*<br/> #14 surg* NEAR/5 wound*<br/> #15 surg* NEAR/5 site*<br/> #16 surg* NEAR/5 incision*<br/> #17 surg* NEAR/5 dehisc*<br/> #18 wound* NEAR/5 dehisc*<br/> #19 (deep NEXT infection*) or "deep sepsis" or (infected NEXT<br/> collection*)<br/> #20 (#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR<br/> #18 OR #19)<br/> #21 MeSH descriptor Anti‐Bacterial Agents explode all trees<br/> #22 MeSH descriptor Cephalosporins explode all trees<br/> #23 MeSH descriptor Tetracycline explode all trees<br/> #24 MeSH descriptor Penicillins explode all trees<br/> #25 antibiotic* or penicillin* or beta‐lactam* or cephalosporin* or clindamycin or trimethoprim* or tetracycline* or doxycycline or minocycline or linezolid or vancomycin or daptomycin or telavancin or rifampicin or gentamycin or gentamicin or fluoroquinolone<br/> #26 (#21 OR #22 OR #23 OR #24 OR #25)<br/> #27 (#8 AND #20 AND #26) </p> <p>The search strategies for Ovid MEDLINE, Ovid EMBASE and EBSCO CINAHL can be found in <a href="./appendices#CD010268-sec-0095">Appendix 1</a>. We combined the Ovid MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity‐ and precision‐maximising version (2008 revision) (<a href="./references#CD010268-bbs2-0070" title="LefebvreC , ManheimerE , Glanville J on behalf of the Cochrane Information Retrieval Methods Group. Chapter 6:  Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Lefebvre 2011</a>). We combined the EMBASE search with the Ovid EMBASE filter developed by the UK Cochrane Centre (<a href="./references#CD010268-bbs2-0070" title="LefebvreC , ManheimerE , Glanville J on behalf of the Cochrane Information Retrieval Methods Group. Chapter 6:  Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Lefebvre 2011</a>). We combined the CINAHL searches with the trial filters developed by the Scottish Intercollegiate Guidelines Network (<a href="./references#CD010268-bbs2-0094" title="Scottish Intercollegiate Guidelines Network (SIGN). Search filters. http://www.sign.ac.uk/methodology/filters.html#random (Accessed May 23 2013). ">SIGN 2013</a>). We did not restrict studies with respect to language, date of publication or study setting. </p> <p>We searched the metaRegister of Controlled Trials (mRCT) (http://www.controlled‐trials.com/mrct/), which includes the ISRCTN Register and the NIH ClinicalTrials.gov Register among others. We also searched the World Health Organization's International Clinical Trials Registry Platform (ICTRP) (http://apps.who.int/trialsearch/). The ICRTP portal includes national trial registry databases from a number of countries (last searched 11 December 2012). </p> </section> <section id="CD010268-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We searched the references of the included trials to identify further relevant trials. We also contacted experts in MRSA infection to identify further trials. </p> </section> </section> <section id="CD010268-sec-0040"> <h3 class="title" id="CD010268-sec-0040">Data collection and analysis</h3> <p>We performed the systematic review following the instructions in the <i>Cochrane Handbook for Systematic Reviews of Intervention</i> (<a href="./references#CD010268-bbs2-0056" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Colloboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). </p> <section id="CD010268-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (KG and RK) identified the trials for inclusion independently. We have listed the excluded studies with reasons for their exclusion. Any differences were resolved through discussion. </p> </section> <section id="CD010268-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Both review authors extracted the following data independently:</p> <p> <ol id="CD010268-list-0005"> <li> <p>Year and language of publication of trial report.</p> </li> <li> <p>Country.</p> </li> <li> <p>Year in which trial was conducted.</p> </li> <li> <p>Inclusion and exclusion criteria.</p> </li> <li> <p>Sample size.</p> </li> <li> <p>Type of surgery.</p> </li> <li> <p>Details of antibiotic treatment including dose, route, frequency, and duration.</p> </li> <li> <p>Outcomes (described above).</p> </li> <li> <p>Risk of bias (described below).</p> </li> <li> <p>Source of funding.</p> </li> </ol> </p> <p>When multiple reports had been published for a trial, we obtained information from all the reports. We contacted the authors of the individual trials to seek out any unclear or missing information. If there was any doubt about whether the trials shared the same participants, completely or partially (by identifying common authors and centres), we contacted the study authors to clarify whether the trial report had been duplicated. We resolved any differences in opinion through discussion. </p> </section> <section id="CD010268-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We followed the instructions in the <i>Cochrane Handbook for Systematic Reviews of Intervention</i> to assess risk of bias (<a href="./references#CD010268-bbs2-0057" title="HigginsJPT , AltmanDG , on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (editors). Chapter 8:  Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). According to empirical evidence (<a href="./references#CD010268-bbs2-0065" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. ">Kjaergard 2001</a>; <a href="./references#CD010268-bbs2-0075" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. ">Moher 1998</a>; <a href="./references#CD010268-bbs2-0088" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. ">Schulz 1995</a>; <a href="./references#CD010268-bbs2-0098" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanGD , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7544):601‐5. ">Wood 2008</a>), the risk of bias of the trials was assessed according to the following bias risk domains: </p> <section id="CD010268-sec-0044"> <h5 class="title">Sequence generation</h5> <p> <ol id="CD010268-list-0006"> <li> <p>Low risk of bias (the methods used are either adequate (e.g. computer‐generated random numbers, table of random numbers) or unlikely to introduce confounding). </p> </li> <li> <p>Uncertain risk of bias (there is insufficient information to assess whether the method used is likely to introduce confounding). </p> </li> <li> <p>High risk of bias (the method used (e.g. quasi‐randomised studies) is improper and likely to introduce confounding). Such studies will be excluded. </p> </li> </ol> </p> </section> <section id="CD010268-sec-0045"> <h5 class="title">Allocation concealment</h5> <p> <ol id="CD010268-list-0007"> <li> <p>Low risk of bias (the method used (e.g. central allocation) is unlikely to induce bias on the final observed effect). </p> </li> <li> <p>Uncertain risk of bias (there is insufficient information to assess whether the method used is likely to induce bias on the estimate of effect). </p> </li> <li> <p>High risk of bias (the method used (e.g. open random allocation schedule) is likely to induce bias on the final observed effect). </p> </li> </ol> </p> </section> <section id="CD010268-sec-0046"> <h5 class="title">Blinding of participants, personnel</h5> <p> <ol id="CD010268-list-0008"> <li> <p>Low risk of bias (blinding was performed adequately, or the outcome measurement is not likely to be influenced by lack of blinding). </p> </li> <li> <p>Uncertain risk of bias (there is insufficient information to assess whether the type of blinding used is likely to induce bias on the estimate of effect). </p> </li> <li> <p>High risk of bias (no blinding or incomplete blinding, and the outcome or the outcome measurement is likely to be influenced by lack of blinding). </p> </li> </ol> </p> </section> <section id="CD010268-sec-0047"> <h5 class="title">Blinding of outcome assessors</h5> <p> <ol id="CD010268-list-0009"> <li> <p>Low risk of bias (blinding was performed adequately, or the outcome measurement is not likely to be influenced by lack of blinding). </p> </li> <li> <p>Uncertain risk of bias (there is insufficient information to assess whether the type of blinding used is likely to induce bias on the estimate of effect). </p> </li> <li> <p>High risk of bias (no blinding or incomplete blinding, and the outcome or the outcome measurement is likely to be influenced by lack of blinding). </p> </li> </ol> </p> </section> <section id="CD010268-sec-0048"> <h5 class="title">Incomplete outcome data</h5> <p> <ol id="CD010268-list-0010"> <li> <p>Low risk of bias (the underlying reasons for missing data are unlikely to make treatment effects depart from plausible values, or proper methods have been employed to handle missing data). </p> </li> <li> <p>Uncertain risk of bias (there is insufficient information to assess whether the missing data mechanism in combination with the method used to handle missing data is likely to induce bias on the estimate of effect). </p> </li> <li> <p>High risk of bias (the crude estimate of effects (e.g. complete case estimate) will clearly be biased due to the underlying reasons for the data being missing, and the methods used to handle missing data are unsatisfactory). </p> </li> </ol> </p> </section> <section id="CD010268-sec-0049"> <h5 class="title">Selective outcome reporting</h5> <p> <ol id="CD010268-list-0011"> <li> <p>Low risk of bias (the trial protocol is available and all of the trial's pre‐specified outcomes that are of interest in the review have been reported or similarly, if the trial protocol is not available, all the primary outcomes in this review are reported). </p> </li> <li> <p>Uncertain risk of bias (there is insufficient information to assess whether the magnitude and direction of the observed effect is related to selective outcome reporting). </p> </li> <li> <p>High risk of bias (not all of the trial's pre‐specified primary outcomes have been reported). </p> </li> </ol> </p> <p>We considered trials that were classified as having a low risk of bias in all the above domains to be low bias‐risk trials. </p> </section> </section> <section id="CD010268-sec-0050"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous variables, we calculated the risk ratio (RR) with 95% confidence interval (CI). We used Peto's odds ratios (Peto OR) for outcomes with a proportion of less than 1% events. For continuous variables, we planned to calculate the mean difference (MD) with 95% CI for outcomes such as hospital stay and standardised mean difference (SMD) with 95% CI for quality of life (where different scales might be used). For time‐to‐event outcomes such as survival at maximal follow‐up, we planned to calculate the hazard ratio (HR) with 95% CI. </p> </section> <section id="CD010268-sec-0051"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was individual people undergoing surgical procedures. We did anticipate the need for people to have a second operation during the same admission within the trials. However, we decided that if we found any person having a second operation, provided that s/he did not have MRSA infection before the second surgery, we would consider each surgery to be a separate unit of analysis. </p> </section> <section id="CD010268-sec-0052"> <h4 class="title">Dealing with missing data</h4> <p>We performed an intention‐to‐treat analysis whenever possible (<a href="./references#CD010268-bbs2-0077" title="NewellDJ . Intention‐to‐treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology1992;21(5):837‐41. ">Newell 1992</a>). We imputed missing data for binary outcomes using various scenarios such as best‐best scenario, worst‐worst scenario, best‐worst scenario, and worst‐best scenario (<a href="./references#CD010268-bbs2-0052" title="GurusamyKS , GluudC , NikolovaD , DavidsonBR . Assessment of risk of bias in randomized clinical trials in surgery. British Journal of Surgery2009;96(4):342‐9. ">Gurusamy 2009</a>). In the best‐best scenario, the people with the missing outcomes were considered not to have developed a complication. In the worst‐worst scenario, the people with the missing outcomes were considered to have developed a complication. In the best‐worst scenario, the people with the missing outcomes were considered not to have developed a complication in the intervention group and to have developed a complication in the control group. In the worst‐best scenario, the people with the missing outcomes were considered to have developed a complication in the intervention group and not to have developed a complication in the control group. </p> <p>For continuous outcomes, we planned to use available‐case analysis. We planned to impute the standard deviation from P values according to the instructions in the <i>Cochrane Handbook for Systematic Reviews of Intervention</i> (<a href="./references#CD010268-bbs2-0058" title="HigginsJPT , Deeks JJ and Altman DG on behalf of the Cochrane Statistical Methods Group (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011c</a>), and use the median for the meta‐analysis when the mean was not available. If it was not possible to calculate the standard deviation from the P value or the CIs, we planned to impute the standard deviation as the highest standard deviation in the other trials included under that outcome, fully recognising that this form of imputation would decrease the weight of the study for calculation of MD and bias the effect estimate to no effect in case of SMD (<a href="./references#CD010268-bbs2-0058" title="HigginsJPT , Deeks JJ and Altman DG on behalf of the Cochrane Statistical Methods Group (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011c</a>). </p> <p>For time‐to‐event outcomes, where HR and 95% CIs were not reported, we planned to obtain the logarithm of hazard ratios (ln(HR)) and the standard error (SE) of ln(HR) according to the methods described by <a href="./references#CD010268-bbs2-0081" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>. </p> </section> <section id="CD010268-sec-0053"> <h4 class="title">Assessment of heterogeneity</h4> <p>We explored heterogeneity by means of the Chi<sup>2</sup> test with significance set at P value 0.10, and measured the degree of heterogeneity by means of the I<sup>2</sup> test (<a href="./references#CD010268-bbs2-0055" title="HigginsJPT , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. ">Higgins 2002</a>). We also used overlapping of CIs on the forest plot to determine heterogeneity. </p> </section> <section id="CD010268-sec-0054"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to use visual asymmetry on a funnel plot to explore reporting bias in the presence of at least 10 trials (<a href="./references#CD010268-bbs2-0048" title="EggerM , DaveySG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>; <a href="./references#CD010268-bbs2-0074" title="MacaskillP , WalterSD , IrwigL . A comparison of methods to detect publication bias in meta‐analysis. Statistics in Medicine2001;20(4):641‐54. ">Macaskill 2001</a>). We planned to perform the linear regression approach described by <a href="./references#CD010268-bbs2-0048" title="EggerM , DaveySG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a> to determine the funnel plot asymmetry. </p> </section> <section id="CD010268-sec-0055"> <h4 class="title">Data synthesis</h4> <p>For the comparison of antibiotic versus placebo (or no intervention), we planned to perform the meta‐analysis only if there was sufficient clinical homogeneity in terms of people included in the trials. This was based on our clinical judgement. For the comparison of different antibiotics, we planned to perform the meta‐analysis only if there was sufficient clinical homogeneity in terms of people included in the trials and in terms of antibiotics used (i.e. similar class of antibiotics). We performed the meta‐analyses using the software package RevMan 5 (<a href="./references#CD010268-bbs2-0084" title="Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>), following the recommendations of The Cochrane Collaboration (<a href="./references#CD010268-bbs2-0056" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Colloboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). We used both a random‐effects model (<a href="./references#CD010268-bbs2-0045" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>), and a fixed‐effect model (<a href="./references#CD010268-bbs2-0044" title="DeMetsDL . Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine1987;6(3):341‐50. ">DeMets 1987</a>), for the meta‐analyses. In case of discrepancy between the two models identified from the pooled estimates and their CIs, we have reported both results; otherwise we have reported the results of the fixed‐effect model. Calculations for dichotomous outcomes to produce risk ratio (RR) or Peto OR do not include trials in which no events occurred in either group in the meta‐analysis, whereas risk difference (RD) calculations do. We planned to report the RD when the results using this association measure were different from RR or Peto OR. However, RR or Peto OR were the measures that we used to arrive at conclusions, since they perform better than RD when there are differences in the control event rate (proportion of people who develop the event in the control). We planned to use the generic inverse variance method to combine the HRs for time‐to‐event outcomes. </p> </section> <section id="CD010268-sec-0056"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform the following subgroup analyses.</p> <p> <ol id="CD010268-list-0012"> <li> <p>Different antibiotics (or class of antibiotics).</p> </li> <li> <p>Different doses and durations of antibiotics.</p> </li> <li> <p>Different types of surgery including different types of wounds (clean, clean‐contaminated, contaminated, and dirty or infected) (the risk of SSI varies according to wound types) (<a href="./references#CD010268-bbs2-0050" title="GarnerJS . CDC guideline for prevention of surgical wound infections, 1985. Infection Control1986;7(3):193‐200. ">Garner 1986</a>). </p> </li> <li> <p>Different patient characteristics (presence of systemic illness such as diabetes or other immunocompromised individuals). </p> </li> <li> <p>People routinely screened and treated versus those who were not routinely screened.</p> </li> </ol> </p> <p>We planned to use a P value of less than 0.05 for the Chi<sup>2</sup> test to identify the differences between subgroups and to investigate whether heterogeneity in effect estimates were attributable to differences in the above characteristics. </p> </section> <section id="CD010268-sec-0057"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis by imputing data for binary outcomes using various scenarios such as best‐best scenario, worst‐worst scenario, best‐worst scenario, and worst‐best scenario (<a href="./references#CD010268-bbs2-0052" title="GurusamyKS , GluudC , NikolovaD , DavidsonBR . Assessment of risk of bias in randomized clinical trials in surgery. British Journal of Surgery2009;96(4):342‐9. ">Gurusamy 2009</a>). We also planned to perform a sensitivity analysis by testing the effect of removing trials at unclear or high risk of bias and excluding the trials in which the mean and the standard deviation were imputed. </p> <section id="CD010268-sec-0058"> <h5 class="title">Presentation of results</h5> <p>We have presented the main results of the review in 'Summary of findings' tables, which provide key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the main outcomes, as recommended by the Cochrane Collaboration (<a href="./references#CD010268-bbs2-0089" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schunemann 2011a</a>). We planned to include the following in the 'Summary of findings' tables: </p> <p> <ol id="CD010268-list-0013"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Serious adverse events.</p> </li> <li> <p>Quality of life.</p> </li> <li> <p>Total length of hospital stay.</p> </li> <li> <p>Use of healthcare resources.</p> </li> <li> <p>Rates of surgical site infections due to MRSA within 30 days of surgery.</p> </li> <li> <p>Rates of surgical site infections due to all organisms within 30 days of surgery.</p> </li> <li> <p>Rates of overall MRSA infections.</p> </li> </ol> </p> <p>We have included 'Summary of findings' tables for the above outcomes when they were available from the trials. Each 'Summary of findings' table includes an overall grading of the evidence related to each of the main outcomes, using the GRADE approach (<a href="./references#CD010268-bbs2-0090" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schunemann 2011b</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010268-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010268-sec-0059"></div> <section id="CD010268-sec-0060"> <h3 class="title">Description of studies</h3> <section id="CD010268-sec-0061"> <h4 class="title">Results of the search</h4> <p>We identified a total of 489 unique references through electronic searches. We excluded 454 clearly irrelevant references through reading titles and abstracts. We retrieved 35 references in full for further assessment. We did not identify any additional references to trials by scanning reference lists of included trials. We did not identify any new trials through other searches. We excluded 22 references because of the reasons mentioned in the <a href="./references#CD010268-sec-0106" title="">Characteristics of excluded studies</a>. Thirteen references to 12 trials met the inclusion criteria and were included in this review (<a href="./references#CD010268-bbs2-0001" title="Carsenti‐EtesseH , DoyonF , DesplacesN , GageyO , TancrèdeC , PradierC , et al. Epidemiology of bacterial infection during management of open leg fractures. European Journal of Clinical Microbiology &amp; Infectious Diseases1999;18(5):315‐23. ">Carsenti‐Etesse 1999</a>; <a href="./references#CD010268-bbs2-0002" title="GoldsteinEJ , CitronDM , MerriamCV , AbramsonMA . Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surgical Infections2009;10(2):111‐8. ">Goldstein 2009</a>; <a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0006" title="KaiserAB , PetracekMR , LeaJW , KernodleDS , RoachAC , AlfordWC , et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double‐blind trial in 1030 patients. Annals of Surgery1987;206(6):791‐7. ">Kaiser 1987</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>; <a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>; <a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). The reference flow is shown in <a href="#CD010268-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010268-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010268-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010268-sec-0062"> <h4 class="title">Included studies</h4> <p>A total of 5284 people were randomised to different antibiotic regimens in the 12 trials (<a href="./references#CD010268-bbs2-0001" title="Carsenti‐EtesseH , DoyonF , DesplacesN , GageyO , TancrèdeC , PradierC , et al. Epidemiology of bacterial infection during management of open leg fractures. European Journal of Clinical Microbiology &amp; Infectious Diseases1999;18(5):315‐23. ">Carsenti‐Etesse 1999</a>; <a href="./references#CD010268-bbs2-0002" title="GoldsteinEJ , CitronDM , MerriamCV , AbramsonMA . Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surgical Infections2009;10(2):111‐8. ">Goldstein 2009</a>; <a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0006" title="KaiserAB , PetracekMR , LeaJW , KernodleDS , RoachAC , AlfordWC , et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double‐blind trial in 1030 patients. Annals of Surgery1987;206(6):791‐7. ">Kaiser 1987</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>; <a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>; <a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). A total of 580 people were excluded from the analysis in eight trials (<a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0006" title="KaiserAB , PetracekMR , LeaJW , KernodleDS , RoachAC , AlfordWC , et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double‐blind trial in 1030 patients. Annals of Surgery1987;206(6):791‐7. ">Kaiser 1987</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>; <a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>; <a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). The proportion of drop‐outs in these trials ranged from 2% to 33%. There were no post‐randomisation drop‐outs in one trial (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>). Information on post‐randomisation drop‐outs was not available in three trials (<a href="./references#CD010268-bbs2-0001" title="Carsenti‐EtesseH , DoyonF , DesplacesN , GageyO , TancrèdeC , PradierC , et al. Epidemiology of bacterial infection during management of open leg fractures. European Journal of Clinical Microbiology &amp; Infectious Diseases1999;18(5):315‐23. ">Carsenti‐Etesse 1999</a>; <a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>). A total of 4704 people were included under the various comparisons. The average age of participants ranged between 54 years and 71 years in the five trials that reported this information (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>; <a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>). Four trials reported adult age as an inclusion criteria (<a href="./references#CD010268-bbs2-0001" title="Carsenti‐EtesseH , DoyonF , DesplacesN , GageyO , TancrèdeC , PradierC , et al. Epidemiology of bacterial infection during management of open leg fractures. European Journal of Clinical Microbiology &amp; Infectious Diseases1999;18(5):315‐23. ">Carsenti‐Etesse 1999</a>; <a href="./references#CD010268-bbs2-0002" title="GoldsteinEJ , CitronDM , MerriamCV , AbramsonMA . Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surgical Infections2009;10(2):111‐8. ">Goldstein 2009</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>; <a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>). One trial stated children as an inclusion criterion (<a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>). From the age range of the included participants, it was possible to identify that three trials included adults only (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>). The information on the age of those included was not reported in the remaining trials (<a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0006" title="KaiserAB , PetracekMR , LeaJW , KernodleDS , RoachAC , AlfordWC , et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double‐blind trial in 1030 patients. Annals of Surgery1987;206(6):791‐7. ">Kaiser 1987</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). The proportion of females ranged between 20.7% and 100% in the six trials that reported this information (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>; <a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). </p> <p>Four trials involved elective colorectal surgeries (<a href="./references#CD010268-bbs2-0002" title="GoldsteinEJ , CitronDM , MerriamCV , AbramsonMA . Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surgical Infections2009;10(2):111‐8. ">Goldstein 2009</a>; <a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>), one trial percutaneous endoscopic gastrostomy (<a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>), one trial surgery for breast cancer (<a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>), two trials cardiac surgery (<a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>), one trial surgery requiring sternotomy (<a href="./references#CD010268-bbs2-0006" title="KaiserAB , PetracekMR , LeaJW , KernodleDS , RoachAC , AlfordWC , et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double‐blind trial in 1030 patients. Annals of Surgery1987;206(6):791‐7. ">Kaiser 1987</a>), and two trials involved open fracture fixation (<a href="./references#CD010268-bbs2-0001" title="Carsenti‐EtesseH , DoyonF , DesplacesN , GageyO , TancrèdeC , PradierC , et al. Epidemiology of bacterial infection during management of open leg fractures. European Journal of Clinical Microbiology &amp; Infectious Diseases1999;18(5):315‐23. ">Carsenti‐Etesse 1999</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>). In one trial of cardiac surgery, all the participants were either positive for nasal carriage of MRSA or had previous MRSA infections (<a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>). However, it is not clear whether MRSA carrier status was treated prior to surgery. One trial clearly stated that the baseline MRSA screening status was not available for participants (<a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>). One trial stated that routine screening was used, but, considering that the participants had open fractures, it is highly unlikely that MRSA was eradicated prior to surgery (<a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>). Information about whether people were routinely screened and treated prior to operation was not reported in the remaining trials (<a href="./references#CD010268-bbs2-0001" title="Carsenti‐EtesseH , DoyonF , DesplacesN , GageyO , TancrèdeC , PradierC , et al. Epidemiology of bacterial infection during management of open leg fractures. European Journal of Clinical Microbiology &amp; Infectious Diseases1999;18(5):315‐23. ">Carsenti‐Etesse 1999</a>; <a href="./references#CD010268-bbs2-0002" title="GoldsteinEJ , CitronDM , MerriamCV , AbramsonMA . Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surgical Infections2009;10(2):111‐8. ">Goldstein 2009</a>; <a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0006" title="KaiserAB , PetracekMR , LeaJW , KernodleDS , RoachAC , AlfordWC , et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double‐blind trial in 1030 patients. Annals of Surgery1987;206(6):791‐7. ">Kaiser 1987</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>; <a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). From the inclusion criteria in the trials, it appears that all the trials included at least some people without systemic illness such as diabetes. </p> <p>Nine trials directly compared two prophylactic antibiotic regimens (<a href="./references#CD010268-bbs2-0001" title="Carsenti‐EtesseH , DoyonF , DesplacesN , GageyO , TancrèdeC , PradierC , et al. Epidemiology of bacterial infection during management of open leg fractures. European Journal of Clinical Microbiology &amp; Infectious Diseases1999;18(5):315‐23. ">Carsenti‐Etesse 1999</a>; <a href="./references#CD010268-bbs2-0002" title="GoldsteinEJ , CitronDM , MerriamCV , AbramsonMA . Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surgical Infections2009;10(2):111‐8. ">Goldstein 2009</a>; <a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>; <a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). Of the remaining three trials, one compared three prophylactic antibiotic regimens (<a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>), one compared four prophylactic antibiotic regimens (<a href="./references#CD010268-bbs2-0006" title="KaiserAB , PetracekMR , LeaJW , KernodleDS , RoachAC , AlfordWC , et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double‐blind trial in 1030 patients. Annals of Surgery1987;206(6):791‐7. ">Kaiser 1987</a>), and one compared a prophylactic antibiotic regimen with placebo (<a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>). A total of 17 comparisons were possible from the data in the 12 included trials. The individual characteristics in trials including inclusion and exclusion criteria, post‐randomisation drop‐outs (and reasons for post‐randomisation drop‐outs), demographic characteristics, antibiotic regimens used, number of people included for analysis for the different antibiotic regimens and the outcomes reported are summarised in <a href="./references#CD010268-sec-0105" title="">Characteristics of included studies</a>. </p> </section> <section id="CD010268-sec-0063"> <h4 class="title">Excluded studies</h4> <p>A total of 22 studies were excluded for the reasons stated in <a href="./references#CD010268-sec-0106" title="">Characteristics of excluded studies</a>. Three reports were not RCTs (<a href="./references#CD010268-bbs2-0013" title="Al‐MukhtarA , WongVK , MalikHZ , Abu‐HilalM , DentonM , WilcoxM , et al. A simple prophylaxis regimen for MRSA: its impact on the incidence of infection in patients undergoing liver resection. Annals of the Royal College of Surgeons of England2009;91(1):35‐8. ">Al‐Mukhtar 2009</a>; <a href="./references#CD010268-bbs2-0017" title="DiehrS , HampA , JamiesonB . Do topical antibiotics improve wound healing?. Journal of Family Practice2007;56(2):140‐4. ">Diehr 2007</a>; <a href="./references#CD010268-bbs2-0021" title="KatoD , MaezawaK , YonezawaI , IwaseY , IkedaH , NozawaM , et al. Randomized prospective study on prophylactic antibiotics in clean orthopedic surgery in one ward for 1 year. Journal of Orthopaedic Science2006;11(1):20‐7. ">Kato 2006</a>); five studies were quasi‐randomised studies (<a href="./references#CD010268-bbs2-0018" title="FinkelsteinR , RabinoG , MashiahT , Bar‐ElY , AdlerZ , KertzmanV , et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin‐resistant staphylococcal infections. Journal of Thoracic and Cardiovascular Surgery2002;123(2):326‐32. ">Finkelstein 2002</a>; <a href="./references#CD010268-bbs2-0020" title="KanellakopoulouK , PapadopoulosA , VarvaroussisD , VarvaroussisA , Giamarellos‐BourboulisEJ , PagonasA , et al. Efficacy of teicoplanin for the prevention of surgical site infections after total hip or knee arthroplasty: a prospective, open‐label study. International Journal of Antimicrobial Agents2009;33(5):437‐40. ">Kanellakopoulou 2009</a>; <a href="./references#CD010268-bbs2-0030" title="SalminenUS , ViljanenTU , ValtonenVV , IkonenTE , SahlmanAE , HarjulaAL . Ceftriaxone versus vancomycin prophylaxis in cardiovascular surgery. Journal of Antimicrobial Chemotherapy1999;44(2):287‐90. ">Salminen 1999</a>; <a href="./references#CD010268-bbs2-0031" title="TacconelliE , CataldoMA , AlbaneseA , TumbarelloM , ArduiniE , SpanuT , et al. Vancomycin versus cefazolin prophylaxis for cerebrospinal shunt placement in a hospital with a high prevalence of meticillin‐resistant Staphylococcus aureus. Journal of Hospital Infection2008;69(4):337‐44. ">Tacconelli 2008</a>; <a href="./references#CD010268-bbs2-0032" title="TyllianakisME , KarageorgosA , MarangosMN , SaridisAG , LambirisEE . Antibiotic prophylaxis in primary hip and knee arthroplasty: comparison between cefuroxime and two specific antistaphylococcal agents. Journal of Arthroplasty2010;25(7):1078‐82. ">Tyllianakis 2010</a>); 12 studies did not report the methicillin resistance status of the cultured organisms (<a href="./references#CD010268-bbs2-0014" title="BluhmG , JacobsonB , JulanderI , Levander‐LindgrenM , OlinC . Antibiotic prophylaxis in pacemaker surgery‐‐a prospective study. Scandinavian Journal of Thoracic and Cardiovascular Surgery1984;18(3):227‐34. ">Bluhm 1984</a>; <a href="./references#CD010268-bbs2-0016" title="DhadwalK , Al‐RuzzehS , AthanasiouT , ChoudhuryM , TekkisP , VuddamalayP , et al. Comparison of clinical and economic outcomes of two antibiotic prophylaxis regimens for sternal wound infection in high‐risk patients following coronary artery bypass grafting surgery: a prospective randomised double‐blind controlled trial. Heart2007;93(9):1126‐33. ">Dhadwal 2007</a>; <a href="./references#CD010268-bbs2-0019" title="Frimodt‐MollerN , OstriP , PedersenIK , PoulsenSR . Antibiotic prophylaxis in pulmonary surgery: a double‐blind study of penicillin versus placebo. Annals of Surgery1982;195(4):444‐50. ">Frimodt‐Moller 1982</a>; <a href="./references#CD010268-bbs2-0022" title="KeighleyMR , ArabiY , Alexander‐WilliamsJ , YoungsD , BurdonDW . Comparison between systemic and oral antimicrobial prophylaxis in colorectal surgery. Lancet1979;313(8122):894‐7. ">Keighley 1979</a>; <a href="./references#CD010268-bbs2-0023" title="MakiDG , BohnMJ , StolzSM , KronckeGM , AcherCW , MyerowitzPD . Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double‐blind randomized trial. Journal of Thoracic and Cardiovascular Surgery1992;104(5):1423‐34. ">Maki 1992</a>; <a href="./references#CD010268-bbs2-0024" title="MarroniM , CaoP , FiorioM , MaghiniM , LentiM , RepettoA , et al. Prospective, randomized, double‐blind trial comparing teicoplanin and cefazolin as antibiotic prophylaxis in prosthetic vascular surgery. European Journal of Clinical Microbiology and Infectious Diseases1999;18(3):175‐8. ">Marroni 1999</a>; <a href="./references#CD010268-bbs2-0025" title="MindermannT , ZimmerliW , GratzlO . Randomized placebo‐controlled trial of single‐dose antibiotic prophylaxis with fusidic acid in neurosurgery. Acta Neurochirurgica1993;121(1‐2):9‐11. ">Mindermann 1993</a>; <a href="./references#CD010268-bbs2-0026" title="PalmerDL , PettSB , AklBF . Bacterial wound colonization after broad‐spectrum versus narrow‐spectrum antibiotics. Annals of Thoracic Surgery1995;59(3):626‐31. ">Palmer 1995</a>; <a href="./references#CD010268-bbs2-0028" title="RamosG , RestaM , DelgadoEM , DurlachR , CanigiaLF , BenaimF . Systemic perioperative antibiotic prophylaxis may improve skin autograft survival in patients with acute burns. Journal of Burn Care and Research2008;29(6):917‐23. ">Ramos 2008</a>; <a href="./references#CD010268-bbs2-0029" title="SaginurR , CroteauD , BergeronMG . Comparative efficacy of teicoplanin and cefazolin for cardiac operation prophylaxis in 3027 patients The ESPRIT Group. Journal of Thoracic and Cardiovascular Surgery2000;120(6):1120‐30. ">Saginur 2000</a>; <a href="./references#CD010268-bbs2-0033" title="WeaverM , BurdonDW , YoungsDJ , KeighleyMR . Oral neomycin and erythromycin compared with single‐dose systemic metronidazole and ceftriaxone prophylaxis in elective colorectal surgery. American Journal of Surgery1986;151(4):437‐42. ">Weaver 1986</a>; <a href="./references#CD010268-bbs2-0034" title="WilsonAP , TreasureT , GrunebergRN , SturridgeMF , RossDN . Antibiotic prophylaxis in cardiac surgery: a prospective comparison of two dosage regimens of teicoplanin with a combination of flucloxacillin and tobramycin. Journal of Antimicrobial Chemotherapy1988;21(2):213‐23. ">Wilson 1988</a>); and two studies did not report the methicillin resistance status for all staphylococcal infections (i.e. the methicillin resistance was stated for staphylococcal infections at some sites, but not at others) (<a href="./references#CD010268-bbs2-0015" title="CannKJ , WatkinsRM , GeorgeC , Payne‐JamesJ , CrawfurdE , RogersTR . A trial of mezlocillin versus cefuroxime with or without metronidazole for the prevention of wound sepsis after biliary and gastrointestinal surgery. Journal of Hospital Infection1988;12(3):207‐14. ">Cann 1988</a>; <a href="./references#CD010268-bbs2-0027" title="PoonWS , NgS , WaiS . CSF antibiotic prophylaxis for neurosurgical patients with ventriculostomy: a randomised study. Acta Neurochirurgica. Supplement1998;71:146‐8. ">Poon 1998</a>). </p> </section> </section> <section id="CD010268-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>All the trials were judged to be at high risk of bias as shown in <a href="#CD010268-fig-0002">Figure 2</a> and <a href="#CD010268-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010268-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010268-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD010268-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010268-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD010268-sec-0065"> <h4 class="title">Allocation</h4> <p>Four trials reported acceptable methods of random sequence generation and allocation concealment (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>; <a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>). These four trials were also free from selection bias. One other trial reported an acceptable method of random sequence generation, but did not report on allocation concealment (<a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). The remaining seven trials did not report on random sequence generation or allocation concealment (<a href="./references#CD010268-bbs2-0001" title="Carsenti‐EtesseH , DoyonF , DesplacesN , GageyO , TancrèdeC , PradierC , et al. Epidemiology of bacterial infection during management of open leg fractures. European Journal of Clinical Microbiology &amp; Infectious Diseases1999;18(5):315‐23. ">Carsenti‐Etesse 1999</a>; <a href="./references#CD010268-bbs2-0002" title="GoldsteinEJ , CitronDM , MerriamCV , AbramsonMA . Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surgical Infections2009;10(2):111‐8. ">Goldstein 2009</a>; <a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0006" title="KaiserAB , PetracekMR , LeaJW , KernodleDS , RoachAC , AlfordWC , et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double‐blind trial in 1030 patients. Annals of Surgery1987;206(6):791‐7. ">Kaiser 1987</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>; <a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>). Eight trials were at unclear risk of selection bias (<a href="./references#CD010268-bbs2-0001" title="Carsenti‐EtesseH , DoyonF , DesplacesN , GageyO , TancrèdeC , PradierC , et al. Epidemiology of bacterial infection during management of open leg fractures. European Journal of Clinical Microbiology &amp; Infectious Diseases1999;18(5):315‐23. ">Carsenti‐Etesse 1999</a>; <a href="./references#CD010268-bbs2-0002" title="GoldsteinEJ , CitronDM , MerriamCV , AbramsonMA . Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surgical Infections2009;10(2):111‐8. ">Goldstein 2009</a>; <a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0006" title="KaiserAB , PetracekMR , LeaJW , KernodleDS , RoachAC , AlfordWC , et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double‐blind trial in 1030 patients. Annals of Surgery1987;206(6):791‐7. ">Kaiser 1987</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>; <a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). </p> </section> <section id="CD010268-sec-0066"> <h4 class="title">Blinding</h4> <p>Adequate blinding of participants, personnel and outcome assessors was reported in one trial (<a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>); this trial was free from performance bias and detection bias (<a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>). Two trials reported adequate blinding of outcome assessors (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>), but had inadequate blinding of participants or personnel; these trials were free from detection bias but not performance bias. In one trial, blinding of participants, personnel or outcome assessors was not performed (<a href="./references#CD010268-bbs2-0006" title="KaiserAB , PetracekMR , LeaJW , KernodleDS , RoachAC , AlfordWC , et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double‐blind trial in 1030 patients. Annals of Surgery1987;206(6):791‐7. ">Kaiser 1987</a>); this trial was of high risk of performance bias and detection bias. Information on blinding was not available in the remaining eight trials (<a href="./references#CD010268-bbs2-0001" title="Carsenti‐EtesseH , DoyonF , DesplacesN , GageyO , TancrèdeC , PradierC , et al. Epidemiology of bacterial infection during management of open leg fractures. European Journal of Clinical Microbiology &amp; Infectious Diseases1999;18(5):315‐23. ">Carsenti‐Etesse 1999</a>; <a href="./references#CD010268-bbs2-0002" title="GoldsteinEJ , CitronDM , MerriamCV , AbramsonMA . Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surgical Infections2009;10(2):111‐8. ">Goldstein 2009</a>; <a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>; <a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>; <a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>); these trials were at unclear risk of performance bias and detection bias. </p> </section> <section id="CD010268-sec-0067"> <h4 class="title">Incomplete outcome data</h4> <p>One trial had no post‐randomisation drop‐outs and was free from attrition bias (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>). In one trial, the imputation of missing outcome data under different scenarios did not influence the results and so the impact of post‐randomisation drop‐outs in this trial was minimal as shown in the section 'Sensitivity analysis' (<a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>). This trial was also considered to be low risk of attrition bias. There was unclear or high risk of attrition bias in the remaining trials (<a href="./references#CD010268-bbs2-0001" title="Carsenti‐EtesseH , DoyonF , DesplacesN , GageyO , TancrèdeC , PradierC , et al. Epidemiology of bacterial infection during management of open leg fractures. European Journal of Clinical Microbiology &amp; Infectious Diseases1999;18(5):315‐23. ">Carsenti‐Etesse 1999</a>; <a href="./references#CD010268-bbs2-0002" title="GoldsteinEJ , CitronDM , MerriamCV , AbramsonMA . Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surgical Infections2009;10(2):111‐8. ">Goldstein 2009</a>; <a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0006" title="KaiserAB , PetracekMR , LeaJW , KernodleDS , RoachAC , AlfordWC , et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double‐blind trial in 1030 patients. Annals of Surgery1987;206(6):791‐7. ">Kaiser 1987</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>; <a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). </p> </section> <section id="CD010268-sec-0068"> <h4 class="title">Selective reporting</h4> <p>Important outcomes such as mortality, antibiotic‐related serious adverse events, overall SSIs and MRSA related SSIs were reported in three trials (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>). These three trials were considered to be at low risk of reporting bias, while the remaining trials were considered to be at high risk of reporting bias. </p> </section> <section id="CD010268-sec-0069"> <h4 class="title">Other potential sources of bias</h4> <p>There were no other potential sources of bias in the remaining trials.</p> </section> </section> <section id="CD010268-sec-0070"> <h3 class="title" id="CD010268-sec-0070">Effects of interventions</h3> <p>See: <a href="./full#CD010268-tbl-0001"><b>Summary of findings for the main comparison</b> Antibiotic prophylaxis for the prevention of methicillin‐resistant <i>Staphylococcus aureus</i> (MRSA) infections and related complications in surgical patients: mortality</a>; <a href="./full#CD010268-tbl-0002"><b>Summary of findings 2</b> Antibiotic prophylaxis for the prevention of methicillin‐resistant <i>Staphylococcus aureus</i> (MRSA) infections and related complications in surgical patients: surgical site infection</a>; <a href="./full#CD010268-tbl-0003"><b>Summary of findings 3</b> Antibiotic prophylaxis for the prevention of methicillin‐resistant <i>Staphylococcus aureus</i> (MRSA) infections and related complications in surgical patients: MRSA surgical site infection</a>; <a href="./full#CD010268-tbl-0004"><b>Summary of findings 4</b> Antibiotic prophylaxis for the prevention of methicillin‐resistant <i>Staphylococcus aureus</i> (MRSA) infections and related complications in surgical patients: overall MRSA infections</a> </p> <p>There was not sufficient clinical homogeneity amongst the included studies to perform a meta‐analysis. The effects of interventions are summarised in <a href="./full#CD010268-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD010268-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD010268-tbl-0003">summary of findings Table 3</a>; and <a href="./full#CD010268-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD010268-sec-0071"> <h4 class="title">All‐cause mortality at maximal follow‐up</h4> <p>Four trials reported mortality (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>), with participants followed up until: discharge (<a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>); seven days after the procedure (<a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>); one month after the procedure (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>); and one month after discharge (<a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). One trial compared a prophylactic antibiotic regimen versus placebo for control (<a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>), while the remaining trials compared different antibiotic regimens (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). The overall mortality in these four trials was 14/1401 (1.0%) (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). There were no significant differences in mortality between the intervention and control groups in any of the four comparisons (<a href="./references#CD010268-fig-0004" title="">Analysis 1.1</a>). Using Peto OR as the effect measure (as the proportion of people was fractionally less than 1.0%) did not alter the results. </p> </section> <section id="CD010268-sec-0072"> <h4 class="title">Other serious adverse events</h4> <p>None of the trials reported on overall serious adverse events. Four trials reported serious adverse events related to antibiotics (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>). One of these trials compared an antibiotic regimen with placebo as control (<a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>), while the remaining trials compared different antibiotic regimens directly (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>). There were no antibiotic‐related serious adverse events in any of the 561 people randomised to the seven different antibiotic regimens in these four trials (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>). </p> </section> <section id="CD010268-sec-0073"> <h4 class="title">Quality of life</h4> <p>None of the trials reported quality of life.</p> </section> <section id="CD010268-sec-0074"> <h4 class="title">Total length of hospital stay</h4> <p>None of the trials reported the total length of hospital stay.</p> </section> <section id="CD010268-sec-0075"> <h4 class="title">Use of healthcare resources</h4> <p>None of the trials reported the use of healthcare resources.</p> </section> <section id="CD010268-sec-0076"> <h4 class="title">Surgical site infections due to all organisms</h4> <p>Eleven trials reported SSIs in the different groups (<a href="./references#CD010268-bbs2-0001" title="Carsenti‐EtesseH , DoyonF , DesplacesN , GageyO , TancrèdeC , PradierC , et al. Epidemiology of bacterial infection during management of open leg fractures. European Journal of Clinical Microbiology &amp; Infectious Diseases1999;18(5):315‐23. ">Carsenti‐Etesse 1999</a>; <a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0006" title="KaiserAB , PetracekMR , LeaJW , KernodleDS , RoachAC , AlfordWC , et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double‐blind trial in 1030 patients. Annals of Surgery1987;206(6):791‐7. ">Kaiser 1987</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>; <a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>; <a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). One trial compared an antibiotic regimen with placebo as control (<a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>), while the remaining trials directly compared different antibiotic regimens. Overall, 221/4032 (5.5%) people developed SSIs due to all organisms. There were no significant differences in the proportion of people who developed SSIs between any of the 15 comparisons involving direct comparison of one antibiotic regimen with another (<a href="./references#CD010268-fig-0005" title="">Analysis 1.2</a>). In the comparison involving antibiotic regimen with placebo, the proportion of people who developed SSIs was statistically significantly lower in people who received the antibiotic prophylaxis with co‐amoxiclav or cefotaxime compared with placebo (RR 0.26; 95% CI 0.11 to 0.65; <a href="./references#CD010268-fig-0005" title="">Analysis 1.2</a>) (<a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>). </p> </section> <section id="CD010268-sec-0077"> <h4 class="title">MRSA surgical site infections</h4> <p>All 12 included trials reported SSIs due to MRSA in the different groups. One trial compared an antibiotic regimen with placebo as control (<a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>), while the remaining trials compared different antibiotic regimens. Overall, 46/4704 (1.0%) people developed SSIs due to MRSA. There were no significant differences in the proportion of people who developed SSIs due to MRSA between any of the 16 comparisons involving comparison of one antibiotic regimen with another (<a href="./references#CD010268-fig-0006" title="">Analysis 1.3</a>). In the comparison involving prophylactic antibiotic regimen with placebo, the proportion of people who developed SSIs due to MRSA was statistically significantly lower in people who received the antibiotic prophylaxis with co‐amoxiclav or cefotaxime compared with placebo (RR 0.05; 95% CI 0.00 to 0.83). Using Peto OR as the effect measure (as the proportion of people was fractionally less than 1.0%) did not alter the results. </p> </section> <section id="CD010268-sec-0078"> <h4 class="title">MRSA infections at any site</h4> <p>Two trials reported overall MRSA infections in the different groups (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>); both trials compared different antibiotic regimens. Overall, 19/478 (4.5%) people developed MRSA infections including SSI, chest infection and bacteraemia. There were no significant differences in the proportion of people who developed MRSA infections at any location in these two comparisons (<a href="./references#CD010268-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD010268-sec-0079"> <h4 class="title">Statistical variations</h4> <p>The issue of fixed‐effect versus random‐effects meta‐analysis did not arise because only one trial was included for each comparison. As meta‐analysis was not performed, we did not calculate the risk difference in order to assess the impact of the trials with zero events on the meta‐analysis results. </p> </section> <section id="CD010268-sec-0080"> <h4 class="title">Subgroup analysis</h4> <p>We did not perform any subgroup analysis, as only one trial was included for each outcome. </p> </section> <section id="CD010268-sec-0081"> <h4 class="title">Sensitivity analysis</h4> <p>One trial had no post‐randomisation drop‐out (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>). In three trials, it was not possible to determine whether there were any post‐randomisation drop‐outs (<a href="./references#CD010268-bbs2-0001" title="Carsenti‐EtesseH , DoyonF , DesplacesN , GageyO , TancrèdeC , PradierC , et al. Epidemiology of bacterial infection during management of open leg fractures. European Journal of Clinical Microbiology &amp; Infectious Diseases1999;18(5):315‐23. ">Carsenti‐Etesse 1999</a>; <a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>). In four trials, although there were post‐randomisation drop‐outs, the groups to which the drop‐outs belonged were not reported (<a href="./references#CD010268-bbs2-0002" title="GoldsteinEJ , CitronDM , MerriamCV , AbramsonMA . Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surgical Infections2009;10(2):111‐8. ">Goldstein 2009</a>; <a href="./references#CD010268-bbs2-0006" title="KaiserAB , PetracekMR , LeaJW , KernodleDS , RoachAC , AlfordWC , et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double‐blind trial in 1030 patients. Annals of Surgery1987;206(6):791‐7. ">Kaiser 1987</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>). Sensitivity analysis using imputation of missing outcome data under different scenarios was either not relevant, or could not be performed in these eight trials. Sensitivity analysis using imputation of missing outcome data under different scenarios was performed for six comparisons reported in four trials (<a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>; <a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). In one trial that reported SSI and MRSA SSI (<a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>), there was no change in the results when results were imputed under different scenarios (<a href="./references#CD010268-fig-0011" title="">Analysis 2.4</a>; <a href="./references#CD010268-fig-0017" title="">Analysis 2.10</a>). In another trial that reported mortality, SSI and MRSA SSI (<a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>), all the outcomes were sensitive to imputation under different scenarios (<a href="./references#CD010268-fig-0009" title="">Analysis 2.2</a>; <a href="./references#CD010268-fig-0015" title="">Analysis 2.8</a>; <a href="./references#CD010268-fig-0021" title="">Analysis 2.14</a>). In the remaining two trials (<a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>), some of the outcomes were sensitive to imputation under different scenarios (<a href="./references#CD010268-fig-0010" title="">Analysis 2.3</a>; <a href="./references#CD010268-fig-0012" title="">Analysis 2.5</a>; <a href="./references#CD010268-fig-0014" title="">Analysis 2.7</a>), while others were not sensitive (<a href="./references#CD010268-fig-0008" title="">Analysis 2.1</a>; <a href="./references#CD010268-fig-0013" title="">Analysis 2.6</a>; <a href="./references#CD010268-fig-0016" title="">Analysis 2.9</a>; <a href="./references#CD010268-fig-0018" title="">Analysis 2.11</a>; <a href="./references#CD010268-fig-0019" title="">Analysis 2.12</a>; <a href="./references#CD010268-fig-0020" title="">Analysis 2.13</a>; <a href="./references#CD010268-fig-0022" title="">Analysis 2.15</a>). </p> </section> <section id="CD010268-sec-0082"> <h4 class="title">Reporting bias</h4> <p>Since only one trial was included for each comparison, we did not explore reporting bias using a funnel plot. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010268-sec-0083" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010268-sec-0083"></div> <section id="CD010268-sec-0084"> <h3 class="title" id="CD010268-sec-0084">Summary of main results</h3> <p>In this review, we compared the efficacy of different antibiotic prophylaxis regimens including no antibiotic prophylaxis in preventing MRSA and related postoperative complications in people undergoing surgery. A total of 16 comparisons of different antibiotic regimens were performed in 11 trials (<a href="./references#CD010268-bbs2-0001" title="Carsenti‐EtesseH , DoyonF , DesplacesN , GageyO , TancrèdeC , PradierC , et al. Epidemiology of bacterial infection during management of open leg fractures. European Journal of Clinical Microbiology &amp; Infectious Diseases1999;18(5):315‐23. ">Carsenti‐Etesse 1999</a>; <a href="./references#CD010268-bbs2-0002" title="GoldsteinEJ , CitronDM , MerriamCV , AbramsonMA . Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surgical Infections2009;10(2):111‐8. ">Goldstein 2009</a>; <a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0006" title="KaiserAB , PetracekMR , LeaJW , KernodleDS , RoachAC , AlfordWC , et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double‐blind trial in 1030 patients. Annals of Surgery1987;206(6):791‐7. ">Kaiser 1987</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>; <a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>; <a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). Antibiotic prophylaxis was compared with no antibiotic prophylaxis in one trial (<a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>). A total of 4704 people undergoing various types of surgery were included under the different comparisons in this review. Except for one trial where all the participants were either positive for nasal carriage of MRSA or had previous MRSA infections (no information provided on whether MRSA carriers were treated prior to surgery) (<a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>) , it does not appear that MRSA was eradicated prior to surgery; nor does it appear that there was high prevalence of MRSA carrier status in the people undergoing surgery. The overall short‐term mortality after surgery in four trials that reported mortality was 1.0% (14/1401) (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). Overall, 221/4032 (5.5%) people developed SSIs due to all organisms (<a href="./references#CD010268-bbs2-0001" title="Carsenti‐EtesseH , DoyonF , DesplacesN , GageyO , TancrèdeC , PradierC , et al. Epidemiology of bacterial infection during management of open leg fractures. European Journal of Clinical Microbiology &amp; Infectious Diseases1999;18(5):315‐23. ">Carsenti‐Etesse 1999</a>; <a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0006" title="KaiserAB , PetracekMR , LeaJW , KernodleDS , RoachAC , AlfordWC , et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double‐blind trial in 1030 patients. Annals of Surgery1987;206(6):791‐7. ">Kaiser 1987</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>; <a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>; <a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>), and 46/4704 (1.0%) people developed SSIs due to MRSA (<a href="./references#CD010268-bbs2-0001" title="Carsenti‐EtesseH , DoyonF , DesplacesN , GageyO , TancrèdeC , PradierC , et al. Epidemiology of bacterial infection during management of open leg fractures. European Journal of Clinical Microbiology &amp; Infectious Diseases1999;18(5):315‐23. ">Carsenti‐Etesse 1999</a>; <a href="./references#CD010268-bbs2-0002" title="GoldsteinEJ , CitronDM , MerriamCV , AbramsonMA . Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surgical Infections2009;10(2):111‐8. ">Goldstein 2009</a>; <a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0006" title="KaiserAB , PetracekMR , LeaJW , KernodleDS , RoachAC , AlfordWC , et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double‐blind trial in 1030 patients. Annals of Surgery1987;206(6):791‐7. ">Kaiser 1987</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>; <a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>; <a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>). </p> <p>One trial including 99 participants compared prophylactic co‐amoxiclav with placebo in people undergoing percutaneous endoscopic gastrostomy (<a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>). In this trial, the proportion of people who developed SSIs due to all organisms and those developed SSIs due to MRSA was lower in the antibiotic prophylaxis group compared with placebo (<a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>). Although co‐amoxiclav has significant in‐vitro activity against some strains of MRSA (<a href="./references#CD010268-bbs2-0035" title="AlouL , CafiniF , SevillanoD , UnzuetaI , PrietoJ . In vitro activity of mupirocin and amoxicillin‐clavulanate alone and in combination against staphylococci including those resistant to methicillin. International Journal of Antimicrobial Agents2004;23(5):513‐6. ">Alou 2004</a>; <a href="./references#CD010268-bbs2-0038" title="CantoniL , WengerA , GlauserMP , BilleJ . Comparative efficacy of amoxicillin‐clavulanate, cloxacillin, and vancomycin against methicillin‐sensitive and methicillin‐resistant Staphylococcus aureus endocarditis in rats. The Journal of Infectious Diseases1989;159(5):989‐93. ">Cantoni 1989</a>; <a href="./references#CD010268-bbs2-0082" title="PrietoJ , AguilarL , GimenezMJ , ToroD , Gomez‐LusML , Dal‐ReR , et al. In vitro activities of co‐amoxiclav at concentrations achieved in human serum against the resistant subpopulation of heteroresistant Staphylococcus aureus: a controlled study with vancomycin. Antimicrobial Agents and Chemotherapy1998;42(7):1574‐7. ">Prieto 1998</a>), there is no evidence for significant clinical activity of co‐amoxiclav and it is not one of the antibiotics recommended for MRSA infections (<a href="./references#CD010268-bbs2-0072" title="LiuC , BayerA , CosgroveSE , DaumRS , FridkinSK , GorwitzRJ , et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin‐resistant Staphylococcus aureus infections in adults and children: executive summary. Clinical Infectious Diseases2011;52(3):285‐92. ">Liu 2011</a>). The probable way that co‐amoxiclav decreased MRSA infections was by decreasing the overall infection level, thereby preventing the wounds from becoming infected secondarily. </p> <p>There were no significant differences in short‐term mortality, SSIs, MRSA SSIs or overall MRSA infections in any of these comparisons. These comparisons included additional antibiotics or increased duration of antibiotics. There is currently no evidence that any of the important clinical outcomes are affected by the addition of antibiotics or increased duration of antibiotics. Although, there were no serious adverse events in any of the 561 people randomised to the seven different antibiotic regimens in four trials (<a href="./references#CD010268-bbs2-0004" title="IshibashiK , KuwabaraK , IshiguroT , OhsawaT , OkadaN , MiyazakiT , et al. Short‐term intravenous antimicrobial prophylaxis in combination with preoperative oral antibiotics on surgical site infection and methicillin‐resistant Staphylococcus aureus infection in elective colon cancer surgery: results of a prospective randomized trial. Surgery Today2009;39(12):1032‐9. ">Ishibashi 2009</a>; <a href="./references#CD010268-bbs2-0005" title="IshidaH , YokoyamaM , NakadaH , InokumaS , HashimotoD . Impact of oral antimicrobial prophylaxis on surgical site infection and methicillin‐resistant Staphylococcus aureus infection after elective colorectal surgery. Results of a prospective randomized trial. Surgery Today2001;31(11):979‐83. ">Ishida 2001</a>; <a href="./references#CD010268-bbs2-0008" title="SaadeddinA , FreshwaterDA , FisherNC , JonesBJM . Antibiotic prophylaxis for percutaneous endoscopic gastrostomy for non‐malignant conditions: A double‐blind prospective randomized controlled trial. Alimentary Pharmacology and Therapeutics2005;22(6):565‐70. ">Saadeddin 2005</a>; <a href="./references#CD010268-bbs2-0009" title="SaveliCC , MorganSJ , BelknapRW , RossE , StahelPF , ChausGW , et al. The role of antibiotics in open fractures revisited: Characteristics of Staphylococcus aureus (SA) and susceptibility profile. Surgical infections2011;12(S1):S38‐9. ">Saveli 2011</a>) (this information was not reported in the remaining eight trials (<a href="./references#CD010268-bbs2-0001" title="Carsenti‐EtesseH , DoyonF , DesplacesN , GageyO , TancrèdeC , PradierC , et al. Epidemiology of bacterial infection during management of open leg fractures. European Journal of Clinical Microbiology &amp; Infectious Diseases1999;18(5):315‐23. ">Carsenti‐Etesse 1999</a>; <a href="./references#CD010268-bbs2-0002" title="GoldsteinEJ , CitronDM , MerriamCV , AbramsonMA . Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surgical Infections2009;10(2):111‐8. ">Goldstein 2009</a>; <a href="./references#CD010268-bbs2-0003" title="HashizumeT , NishizawaR , AizawaS , YamayaM , KoboriH , AsakuraY , et al. Clinical study of using prophylactic antibiotics and chemical preparation for elective operation of colorectal cancer. Japanese Journal of Gastroenterological Surgery2004;37(4):375‐83. ">Hashizume 2004</a>; <a href="./references#CD010268-bbs2-0006" title="KaiserAB , PetracekMR , LeaJW , KernodleDS , RoachAC , AlfordWC , et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double‐blind trial in 1030 patients. Annals of Surgery1987;206(6):791‐7. ">Kaiser 1987</a>; <a href="./references#CD010268-bbs2-0007" title="MorimotoK , KohM , KinoshitaH . Levofloxacin for prophylaxis in breast cancer surgery compared with ofloxacin. Japanese Journal of Antibiotics2002;55(6):866‐74. ">Morimoto 2002</a>; <a href="./references#CD010268-bbs2-0010" title="ShimeN , KatoY , KosakaT , KokufuT , YamagishiM , FujitaN . Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. European Journal of Cardio‐Thoracic Surgery2007;32(4):577‐81. ">Shime 2007</a>; <a href="./references#CD010268-bbs2-0011" title="StoneP , CampbellJ , AbuRahmaA , SafleyL , EmmettM , AsmitaM . Vascular surgical antibiotic prophylaxis study (VSAPS). Vascular and Endovascular Surgery2010;44(7):521‐8. StonePA , AbuRahmaAF . Vascular surgical antibiotic prophylactic study (VSAPS). Journal of Vascular Surgery2009;50(6):1533. ">Stone 2010</a>; <a href="./references#CD010268-bbs2-0012" title="VuorisaloS , PokelaR , SyrjalaH . Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infection Control and Hospital Epidemiology1998;19(4):234‐9. ">Vuorisalo 1998</a>)), there are various concerns about increasing the duration or the number of antibiotics in the antibiotic combination. The obvious concern is the cost of the antibiotics. This is important in state‐funded, insurance‐funded, and private‐funded healthcare systems, as unnecessary use of antibiotics increases the cost of procedures (besides the cost of the antibiotic <i>per se</i> , one should also consider the costs for administering the antibiotics). At the individual level, antibiotic‐related adverse events may delay recovery after surgery. While adverse events such as nausea or other gastrointestinal upsets may not be serious adverse events, and are unlikely to be major determinants of the decision about the antibiotic regimens, these mild adverse events may prevent the participant from returning to normal activities, and hence may delay recovery. Although most adverse events related to antibiotics can be managed easily, some adverse events such as severe anaphylactic shock or antibiotic‐related infections (by decreasing the gut flora ‐ for example antibiotic‐induced <i>Clostridium difficile</i> infection can cause pseudomembranous colitis) can be life‐threatening (<a href="./references#CD010268-bbs2-0087" title="SchroederMS . Clostridium difficile‐‐associated diarrhea. American Family Physician2005;71(5):921‐8. ">Schroeder 2005</a>). At the community level, inappropriate and unnecessary use of antibiotics can lead to the development of drug resistance (<a href="./references#CD010268-bbs2-0092" title="SieradzkiK , RobertsRB , HaberSW , TomaszA . The development of vancomycin resistance in a patient with methicillin‐resistant Staphylococcus aureus infection. New England Journal of Medicine1999;340(7):517‐23. ">Sieradzki 1999</a>; <a href="./references#CD010268-bbs2-0041" title="ChuaT , MooreCL , PerriMB , DonabedianSM , MaschW , VagerD , et al. Molecular epidemiology of methicillin‐resistant Staphylococcus aureus bloodstream isolates in urban Detroit. Journal of Clinical Microbiology2008;46(7):2345‐52. ">Chua 2008</a>), which could be problematic for future populations. </p> </section> <section id="CD010268-sec-0085"> <h3 class="title" id="CD010268-sec-0085">Overall completeness and applicability of evidence</h3> <p>A range of surgeries ranging from moderate to major surgeries were included in this review. So, this review is applicable to most types of surgery. This review is applicable only to people who do not have existing MRSA infections<b>.</b> The people included in this review did not appear to be particularly immunocompromised, so the results of this review are not applicable for immunocompromised people. </p> </section> <section id="CD010268-sec-0086"> <h3 class="title" id="CD010268-sec-0086">Quality of the evidence</h3> <p>The overall quality of the evidence is either low, or very low, as shown in <a href="./full#CD010268-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD010268-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD010268-tbl-0003">summary of findings Table 3</a>; and <a href="./full#CD010268-tbl-0004">summary of findings Table 4</a>. The risk of bias was high in all the trials. By using and reporting an appropriate method of randomisation, selection bias could be minimised. In most instances where different antibiotic regimens are compared, it is possible to blind the participants, personnel and outcome assessors by the use of an appropriate placebo. This minimises the performance and detection bias. By performing an intention‐to‐treat analysis, it is possible to decrease attrition bias. By reporting the important clinical outcomes that are likely to be measured routinely, such as mortality, morbidity, antibiotic‐related adverse events, and length of hospital stay, selective outcome reporting could be minimised. Measuring the quality of life and health resource utilisation measures such as hospital or community nurse visits, wound dressings, etc would allow an health economic analysis to determine the cost‐effectiveness of using different antibiotics. Apart from the risk of bias, the other quality issue was that the effect measures were imprecise, i.e. the confidence intervals were wide and one could not rule out a clinically significant benefit or harm related to different antibiotic regimens. This issue can be addressed by appropriate sample size calculations prior to conducting a trial. In spite of all the shortcomings, this is the best available evidence on this topic. </p> </section> <section id="CD010268-sec-0087"> <h3 class="title" id="CD010268-sec-0087">Potential biases in the review process</h3> <p>We have performed a thorough search of the literature without any restrictions regarding language or date of publication. In spite of this, we were not be able to identify any trials that were conducted, but not reported, in the pre‐mandatory trial registration era. We included only trials in which MRSA infection was mentioned. It is highly likely that several other trials on antibiotic regimens have been conducted without assessing or reporting the methicillin resistance status of the organisms. The nature of this topic means that one has to be pragmatic and accept that such trials are unlikely to be identified electronically, and that contacting the authors of every single trial that has assessed prophylactic antibiotics to obtain information regarding whether they measured the MRSA status of the organisms, and to obtain information in a such way that it could be used for this systematic review would be resource intensive. The reliability of information obtained in this manner can also be a major concern. </p> </section> <section id="CD010268-sec-0088"> <h3 class="title" id="CD010268-sec-0088">Agreements and disagreements with other studies or reviews</h3> <p>There have been no previous systematic reviews on this topic.</p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010268-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010268-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/full#CD010268-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010268-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/full#CD010268-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010268-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/full#CD010268-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison of different regimens of prophylactic antibiotics, Outcome 1 Mortality." data-id="CD010268-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Comparison of different regimens of prophylactic antibiotics, Outcome 1 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison of different regimens of prophylactic antibiotics, Outcome 2 Overall surgical site infection." data-id="CD010268-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Comparison of different regimens of prophylactic antibiotics, Outcome 2 Overall surgical site infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison of different regimens of prophylactic antibiotics, Outcome 3 MRSA surgical site infection." data-id="CD010268-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Comparison of different regimens of prophylactic antibiotics, Outcome 3 MRSA surgical site infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison of different regimens of prophylactic antibiotics, Outcome 4 Overall MRSA infections." data-id="CD010268-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Comparison of different regimens of prophylactic antibiotics, Outcome 4 Overall MRSA infections. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis, Outcome 1 Mortality (kanamycin, erythromycin and cefotiam versus cefotiam)." data-id="CD010268-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis, Outcome 1 Mortality (kanamycin, erythromycin and cefotiam versus cefotiam). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis, Outcome 2 Mortality (vancomycin versus cefuroxime)." data-id="CD010268-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis, Outcome 2 Mortality (vancomycin versus cefuroxime).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis, Outcome 3 Surgical site infection (kanamycin, erythromycin and cefotiam versus cefotiam)." data-id="CD010268-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis, Outcome 3 Surgical site infection (kanamycin, erythromycin and cefotiam versus cefotiam). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis, Outcome 4 Surgical site infection (vancomycin versus teicoplanin)." data-id="CD010268-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis, Outcome 4 Surgical site infection (vancomycin versus teicoplanin). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis, Outcome 5 Surgical site infection (vancomycin and cefazolin versus daptomycin and cefazolin)." data-id="CD010268-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis, Outcome 5 Surgical site infection (vancomycin and cefazolin versus daptomycin and cefazolin). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis, Outcome 6 Surgical site infection (vancomycin and cefazolin versus cefazolin)." data-id="CD010268-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis, Outcome 6 Surgical site infection (vancomycin and cefazolin versus cefazolin). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis, Outcome 7 Surgical site infection (daptomycin and cefazolin versus cefazolin)." data-id="CD010268-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis, Outcome 7 Surgical site infection (daptomycin and cefazolin versus cefazolin). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis, Outcome 8 Surgical site infection (vancomycin versus cefuroxime)." data-id="CD010268-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis, Outcome 8 Surgical site infection (vancomycin versus cefuroxime). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis, Outcome 9 MRSA surgical site infection (kanamycin, erythromycin and cefotiam versus cefotiam)." data-id="CD010268-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis, Outcome 9 MRSA surgical site infection (kanamycin, erythromycin and cefotiam versus cefotiam). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis, Outcome 10 MRSA surgical site infection (vancomycin versus teicoplanin)." data-id="CD010268-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis, Outcome 10 MRSA surgical site infection (vancomycin versus teicoplanin). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis, Outcome 11 MRSA surgical site infection (vancomycin and cefazolin versus daptomycin and cefazolin)." data-id="CD010268-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis, Outcome 11 MRSA surgical site infection (vancomycin and cefazolin versus daptomycin and cefazolin). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis, Outcome 12 MRSA surgical site infection (vancomycin and cefazolin versus cefazolin)." data-id="CD010268-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis, Outcome 12 MRSA surgical site infection (vancomycin and cefazolin versus cefazolin). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis, Outcome 13 MRSA surgical site infection (daptomycin and cefazolin versus cefazolin)." data-id="CD010268-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis, Outcome 13 MRSA surgical site infection (daptomycin and cefazolin versus cefazolin). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis, Outcome 14 MRSA surgical site infection (vancomycin versus cefuroxime)." data-id="CD010268-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis, Outcome 14 MRSA surgical site infection (vancomycin versus cefuroxime). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010268-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/urn:x-wiley:14651858:media:CD010268:CD010268-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_t/tCD010268-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis, Outcome 15 Overall MRSA infections (kanamycin, erythromycin and cefotiam versus cefotiam)." data-id="CD010268-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis, Outcome 15 Overall MRSA infections (kanamycin, erythromycin and cefotiam versus cefotiam). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/media/CDSR/CD010268/image_n/nCD010268-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010268-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) infections and related complications in surgical patients: mortality</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> surgical patients<br/> <b>Settings:</b> secondary<br/> <b>Intervention:</b> comparison of different regimens of prophylactic antibiotic regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comparisons</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Comparison of different regimens of prophylactic antibiotic regimens</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>One dose of cefotiam or cefmetazol versus four doses of cefotiam or cefmetazol (elective surgery for colon cancer)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kanamycin, erythromycin and cefotiam versus cefotiam (surgery for colorectal diseases)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Co‐amoxiclav or cefotaxime versus placebo (percutaneous endoscopic gastrostomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>146 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>79 per 1000</b> <br/> (25 to 251) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.54</b> <br/> (0.17 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vancomycin versus cefuroxime (coronary artery bypass graft without valvular disease)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> <br/> (0 to 50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.02</b> <br/> (0.18 to 22.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>884<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk in the study. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> The risk of bias in the trial was high<br/> <sup>2</sup> The confidence intervals overlapped 1 and/or 0.75 and 1.25. There were fewer than 300 events in total in the intervention and control groups </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) infections and related complications in surgical patients: mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/full#CD010268-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010268-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) infections and related complications in surgical patients: surgical site infection</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b>Surgical site infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> surgical patients<br/> <b>Settings:</b> secondary<br/> <b>Intervention:</b> comparison of different regimens of prophylactic antibiotic regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comparisons</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Comparison of different regimens of prophylactic antibiotic regimens</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cefamendole versus cefamendole and gentamycin (median sternotomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 5.08</b> <br/> (0.24 to 105.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>522<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> <br/> (1 to 526) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cefazolin versus cefamendole (median sternotomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b> <br/> (6 to 131) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.55</b> <br/> (0.75 to 16.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>514<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cefazolin versus cefazolin and gentamycin (median sternotomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> <br/> (10 to 75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.87</b> <br/> (0.32 to 2.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>508<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Co‐amoxiclav or cefotaxime versus placebo (percutaneous endoscopic gastrostomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>98 per 1000</b> <br/> (41 to 244) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.26</b> <br/> (0.11 to 0.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daptomycin and cefazolin versus cefazolin (vascular surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b> <br/> (9 to 177) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.3</b> <br/> (0.07 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kanamycin, erythromycin and cefotiam versus cefotiam (surgery for colorectal diseases)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>110 per 1000</b> <br/> (50 to 242) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.46</b> <br/> (0.21 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Levofloxacin versus ofloxacin (breast cancer)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> <br/> (11 to 146) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.66</b> <br/> (0.18 to 2.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>One day of piperacillin, cefazolin, cefmetazole, or cefotiam versus three days of piperacillin, cefazolin, cefmetazole, or cefotiam (elective colorectal surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b> <br/> (28 to 116) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b> <br/> (0.52 to 2.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>One dose of cefotiam or cefmetazol versus four doses of cefotiam or cefmetazol (elective surgery for colon cancer)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>51 per 1000</b> <br/> (19 to 134) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.79</b> <br/> (0.3 to 2.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pefloxacin versus cefazolin and oxacillin (tibial fracture requiring external fixation)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>90 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> <br/> (39 to 115) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b> <br/> (0.43 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>616<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vancomycin and cefazolin versus cefazolin (open fractures)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> <br/> (23 to 327) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1</b> <br/> (0.27 to 3.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vancomycin and cefazolin versus cefazolin (vascular surgery) ‐ suggest add for all comparisons</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> <br/> (49 to 323) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b> <br/> (0.38 to 2.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vancomycin and cefazolin versus daptomycin and cefazolin (vascular surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> <br/> (27 to 575) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.19</b> <br/> (0.69 to 14.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vancomycin versus teicoplanin (paediatric cardiac surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No infection in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vancomycin versus cefuroxime (coronary artery bypass graft without valvular disease)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> <br/> (17 to 70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/> (0.53 to 2.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>884<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> is the control group risk in the study. When there were no events in either group, we have indicated so. When there were events in the intervention group but not in the control group, we have used a moderate proportion of 0.5% in the control group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> The risk of bias in the trial was high<br/> <sup>2</sup> The confidence intervals overlapped 1 and/or 0.75 and 1.25. There were fewer than 300 events in total in the intervention and control groups </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) infections and related complications in surgical patients: surgical site infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/full#CD010268-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010268-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) infections and related complications in surgical patients: MRSA surgical site infection</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>MRSA surgical site infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> surgical patients<br/> <b>Settings:</b> secondary<br/> <b>Intervention:</b> comparison of different regimens of prophylactic antibiotic regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comparisons</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Comparison of different regimens of prophylactic antibiotic regimens</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cefamendole versus cefamendole and gentamycin (median sternotomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No infection in either group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>522<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cefazolin and gentamycin versus cefamendole and gentamycin (median sternotomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No infection in either group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>516<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cefazolin versus cefamendole (median sternotomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.05</b> <br/> (0.12 to 74.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>514<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> <br/> (1 to 372) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Cefazolin versus cefazolin and gentamycin (median sternotomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 2.98</b> <br/> (0.12 to 72.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>508<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>15 per 1000</b> <br/> (1 to 364) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐amoxiclav or cefotaxime versus placebo (percutaneous endoscopic gastrostomy)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>188 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>9 per 1000</b> <br/> (0 to 156) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.05</b> <br/> (0 to 0.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Daptomycin and cefazolin versus cefazolin (vascular surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>8 per 1000</b> <br/> (0 to 159) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.24</b> <br/> (0.01 to 4.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ertapenem versus cefotetan (elective colorectal surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>15 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>9 per 1000</b> <br/> (2 to 37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.59</b> <br/> (0.14 to 2.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>672<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Kanamycin, erythromycin and cefotiam versus cefotiam (surgery for colorectal diseases)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>55 per 1000</b> <br/> (10 to 294) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.97</b> <br/> (0.37 to 10.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Levofloxacin versus ofloxacin (breast cancer)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>No infection in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>181<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>One day of piperacillin, cefazolin, cefmetazole, or cefotiam versus three days of piperacillin, cefazolin, cefmetazole, or cefotiam (elective colorectal surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>No infection in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>521<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>One dose of cefotiam or cefmetazol versus four doses of cefotiam or cefmetazol (elective surgery for colon cancer)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>22 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>22 per 1000</b> <br/> (5 to 107) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.02</b> <br/> (0.21 to 4.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>275<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pefloxacin versus cefazolin and oxacillin (tibial fracture requiring external fixation)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>3 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>13 per 1000</b> <br/> (1 to 113) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.8</b> <br/> (0.43 to 33.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>616<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Vancomycin and cefazolin versus cefazolin (open fractures)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 3</b> <br/> (0.13 to 71.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>92<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>15 per 1000</b> <br/> (1 to 359) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vancomycin and cefazolin versus cefazolin (vascular surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>71 per 1000</b> <br/> (14 to 375) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.21</b> <br/> (0.42 to 11.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Vancomycin and cefazolin versus daptomycin and cefazolin (vascular surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 8.21</b> <br/> (0.45 to 148.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>107<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>41 per 1000</b> <br/> (2 to 744) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vancomycin versus teicoplanin (paediatric cardiac surgery)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>No infection in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vancomycin versus cefuroxime (coronary artery bypass graft without valvular disease)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>5 per 1000</b> <br/> (1 to 32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.01</b> <br/> (0.14 to 7.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>884<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk in the study. When there were no events in either group, we have indicated so. When there were events in the intervention group but not in the control group, we have used a moderate proportion of 0.5% in the control group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> The risk of bias in the trial was high<br/> <sup>2</sup> The confidence intervals overlapped 1 and/or 0.75 and 1.25. There were fewer than 300 events in total in the intervention and control groups </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) infections and related complications in surgical patients: MRSA surgical site infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/full#CD010268-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010268-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) infections and related complications in surgical patients: overall MRSA infections</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>Overall MRSA infections</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> surgical patients<br/> <b>Settings:</b> secondary<br/> <b>Intervention:</b> comparison of different regimens of prophylactic antibiotic regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comparisons</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Comparison of different regimens of prophylactic antibiotic regimens</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>One dose of cefotiam or cefmetazol versus four doses of cefotiam or cefmetazol (elective surgery for colon cancer)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> <br/> (5 to 97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.77</b> <br/> (0.17 to 3.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kanamycin, erythromycin and cefotiam versus cefotiam (surgery for colorectal diseases)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>111 per 1000</b> <br/> (35 to 353) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.97</b> <br/> (0.62 to 6.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk in the study. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> The risk of bias in the trial was high.<br/> <sup>2</sup> The confidence intervals overlapped 1 and/or 0.75 and 1.25. There were fewer than 300 events in total in the intervention and control groups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) infections and related complications in surgical patients: overall MRSA infections</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/full#CD010268-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010268-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison of different regimens of prophylactic antibiotics</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 One dose of cefotiam or cefmetazol versus four doses of cefotiam or cefmetazol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Kanamycin, erythromycin and cefotiam versus cefotiam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Co‐amoxiclav or cefotaxime versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Vancomycin versus cefuroxime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall surgical site infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Cefamendole versus cefamendole and gentamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Cefazolin and gentamycin versus cefamendole and gentamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Cefazolin versus cefamendole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Cefazolin versus cefazolin and gentamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Co‐amoxiclav or cefotaxime versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Daptomycin and cefazolin versus cefazolin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Kanamycin, erythromycin and cefotiam versus cefotiam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Levofloxacin versus ofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 One day of piperacillin, cefazolin, cefmetazole, or cefotiam versus three days of piperacillin, cefazolin, cefmetazole, or cefotiam </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10 One dose of cefotiam or cefmetazol versus four doses of cefotiam or cefmetazol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11 Pefloxacin versus cefazolin and oxacillin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12 Vancomycin and cefazolin versus cefazolin (open fractures)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13 Vancomycin and cefazolin versus cefazolin (vascular surgery)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14 Vancomycin and cefazolin versus daptomycin and cefazolin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15 Vancomycin versus teicoplanin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16 Vancomycin versus cefuroxime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 MRSA surgical site infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Cefamendole versus cefamendole and gentamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Cefazolin and gentamycin versus cefamendole and gentamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Cefazolin versus cefamendole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Cefazolin versus cefazolin and gentamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Co‐amoxiclav or cefotaxime versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Daptomycin and cefazolin versus cefazolin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Ertapenem versus cefotetan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Kanamycin, erythromycin and cefotiam versus cefotiam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 Levofloxacin versus ofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10 One day of piperacillin, cefazolin, cefmetazole, or cefotiam versus three days of piperacillin, cefazolin, cefmetazole, or cefotiam </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11 One dose of cefotiam or cefmetazol versus four doses of cefotiam or cefmetazol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12 Pefloxacin versus cefazolin and oxacillin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13 Vancomycin and cefazolin versus cefazolin (open fractures)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14 Vancomycin and cefazolin versus cefazolin (vascular surgery)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15 Vancomycin and cefazolin versus daptomycin and cefazolin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16 Vancomycin versus teicoplanin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17 Vancomycin versus cefuroxime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Overall MRSA infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 One dose of cefotiam or cefmetazol versus four doses of cefotiam or cefmetazol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Kanamycin, erythromycin and cefotiam versus cefotiam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison of different regimens of prophylactic antibiotics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010268-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sensitivity analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality (kanamycin, erythromycin and cefotiam versus cefotiam) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Best‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Worst‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Best‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Worst‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality (vancomycin versus cefuroxime) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Best‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Worst‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Best‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Worst‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Surgical site infection (kanamycin, erythromycin and cefotiam versus cefotiam) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Best‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Worst‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Best‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Worst‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Surgical site infection (vancomycin versus teicoplanin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Best‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Worst‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Best‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Worst‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Surgical site infection (vancomycin and cefazolin versus daptomycin and cefazolin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Best‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Worst‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Best‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Worst‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Surgical site infection (vancomycin and cefazolin versus cefazolin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Best‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Worst‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Best‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Worst‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Surgical site infection (daptomycin and cefazolin versus cefazolin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Best‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Worst‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Best‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Worst‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Surgical site infection (vancomycin versus cefuroxime) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Best‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Worst‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Best‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Worst‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 MRSA surgical site infection (kanamycin, erythromycin and cefotiam versus cefotiam) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Best‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Worst‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Best‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Worst‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 MRSA surgical site infection (vancomycin versus teicoplanin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Best‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Worst‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Best‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Worst‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 MRSA surgical site infection (vancomycin and cefazolin versus daptomycin and cefazolin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Best‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Worst‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Best‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 Worst‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 MRSA surgical site infection (vancomycin and cefazolin versus cefazolin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Best‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Worst‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Best‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Worst‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 MRSA surgical site infection (daptomycin and cefazolin versus cefazolin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Best‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Worst‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Best‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Worst‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 MRSA surgical site infection (vancomycin versus cefuroxime) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Best‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Worst‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Best‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 Worst‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Overall MRSA infections (kanamycin, erythromycin and cefotiam versus cefotiam) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Best‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Worst‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Best‐worst scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 Worst‐best scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010268.pub2/references#CD010268-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010268.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010268-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010268-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010268-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD010268-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD010268-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010268\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010268\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010268\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010268\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010268\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010268\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010268\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010268\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010268\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010268\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010268\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010268\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010268\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010268\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010268\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010268\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010268\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010268\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010268.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010268.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010268.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010268.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010268.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727682646"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010268.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727682650"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010268.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb1f9bdfb936d',t:'MTc0MDcyNzY4NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 